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ABSTRACT 
Joel Khalil Durand: Investigating the role of DNA methylation and NF-kappaB signaling 
in KRAS-driven cancer 
(Under the direction of Albert S. Baldwin) 
 
Oncogenic Ras mutations are associated with DNA methylation changes that 
alter gene expression relevant to the cancer phenotype. Recent studies suggest these 
DNA methylation changes may be stochastic in nature, while other groups propose 
elaborate pathways responsible for aberrant methylation. Ultimately, a better 
understanding of the DNA methylation events associated with oncogenic KRAS 
expression could enhance therapeutic approaches. 
Here we analyze the basal CpG methylation of 11 KRAS dependent pancreatic 
cancer cell lines and observe strikingly similar basal methylation patterns. However, 
KRAS knockdown results in unique methylation changes with limited overlap between 
each cell line. In Pa16C pancreatic cells, while KRAS knockdown results in over 8000 
differentially methylated (DM) CpGs, treatment with the ERK inhibitor SCH772984 
shows less than 40 DM CpGs, suggesting that ERK is not a broadly active driver of 
KRAS-associated DNA methylation. KRAS G12V overexpression in an isogenic lung 
model reveals >50,600 DM CpGs compared to non-transformed controls. In lung and 
pancreatic cells, gene ontology analyses of the cell line specific DM promoters show 
enrichment for genes involved in differentiation and development. These epigenetically 
 iv 
altered genes associated with KRAS expression could represent potential therapeutic 
targets in KRAS-driven cancer. 
In addition to describing the DNA methylation in KRAS mutant cells, we also aim 
to gain a better understanding of the noncanonical NF-κB pathway and the NF-κB 
transcription factor subunit, RELB, in KRAS mutant cells. Our findings suggest that 
RELB expression is upregulated in KRAS mutant cells in vitro and in vivo. Interestingly, 
in our DNA methylation studies, we observe hypomethylation at the RELB promoter in 
cells expressing KRAS G12V. RNAi against RELB decreases proliferation and 
nonadherent colony growth. However, depletion of RELB did not show significant 
effects on proliferation in murine xenograft and genetic models. Models designed to 
assess migration, metastasis, and cell-state transitions associated with RELB 
expression could yield more actionable results in future studies. These results suggest 
that mutant KRAS leads the upregulation of RELB expression, and supports an 
important role for the noncanonical NF-κB pathway as a potential therapeutic target in 
KRAS-driven malignancies. 
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CHAPTER I: INTRODUCTION1 
1.1. AN OVERVIEW OF RAS SIGNAL TRANSDUCTION 
For cells to function appropriately, they rely on the fidelity of signal transduction 
pathways to transmit molecular signals from extracellular stimuli to the interior of the 
cell. The RAS subfamily of proteins, comprised of HRAS, NRAS, and KRAS, plays a 
crucial role in transmitting extracellular signals and eliciting the appropriate cellular 
responses (Lemmon and Schlessinger, 2010). These small GTPases function as on/off 
switches upstream of a number of important biological processes, including cell cycle 
progression, cell growth, survival, development and differentiation (Schubbert et al., 
2007). 
 
1.1.1. Regulation of the RAS signaling pathways 
The role of RAS proteins as drivers of essential biological processes underscores 
the importance for the pathways to remain well regulated. The RAS proteins are post-
translationally modified, which primarily results in localization to the cytosolic face of the 
plasma membrane (Cox and Der, 1997; Hancock, 2003). Although RAS can be 
activated by several other proteins, the cascade typically begins with the activation of 
receptor tyrosine kinases (RTKs) (Figure 1.1). Growth factor binding leads to activation 
of cell-surface receptors such as RTKs like epidermal-growth-factor receptor (EGFR) 
                                                        
1 Part of this chapter was submitted as a chapter for the book, Targeting IKK and NF-κB for Therapy. 
Advances in Protein Chemistry and Structural Biology, Vol. 107, Burlington: Academic Press, 2017, pp. 
77-115. The following authors contributed to this book chapter: Joel K. Durand and Albert S. Baldwin. 
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(Lemmon and Schlessinger, 2010). Activation of RTKs creates intracellular docking 
sites, which recruit a complex of proteins to the plasma membrane including the adaptor 
protein growth-factor-receptor-bound protein 2 (GRB2) and the guanine nucleotide-
exchange factors (GEFs) in the Son of Sevenless (SOS) family (Downward, 2003). 
Their proximity at the plasma membrane allows the SOS GEF to displace guanosine 
diphosphate (GDP) from the inactive conformation of RAS and results in passive 
binding of the more abundant guanosine nucleotide, GTP (Ostrem et al., 2013). The 
GTP-bound RAS is in its active state. This conformation of RAS interacts with more 
than a dozen effectors in a context-dependent manner, including phosphatidylinositol 3-
kinase (PI3K), RAL guanine nucleotide-dissociation stimulator (RALGDS), and the RAF 
kinases (Mitin et al., 2005; Shaw and Cantley, 2006; Yuan et al., 2018). The RAS 
proteins are able to slowly hydrolyze GTP into GDP; however, GTPase activating 
proteins (GAPs) function to stimulate the intrinsic GTPase activity of RAS, accelerating 
the return to its inactive GDP-bound state. This places GEFs and GAPs as critical 
determinants of the activation state of RAS and its downstream effectors (Bos et al., 
2007; Vigil et al., 2010). Unsurprisingly, the majority of the somatic RAS mutations 
found in cancer cells impair the intrinsic GTPase activity and confer resistance to GAPs 
(Scheffzek et al., 1997). These mutant RAS proteins then accumulate in the active, 
GTP-bound confirmation and lead to aberrant effector signaling (Prior et al., 2012). 
 
1.1.2. The RAS isoforms - a focus on the KRAS isoform in cancer 
The three human RAS genes encode four homologous proteins - HRAS, NRAS, 
KRAS4A, and KRAS4B (Figure 1.2). KRAS4B is the predominant splice variant of the 
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ubiquitously expressed KRAS gene, and is typically just referred to as KRAS. The G 
domain (residues 1-165) is highly conserved between the RAS isoforms and contains 
regions responsible for GDP/GTP binding, GTPase activity, and effector interactions 
(Wittinghofer and Vetter, 2011). Amino acid substitutions at positions 12, 13, and 61 are 
the most frequently observed in cancers. These mutations ultimately impede hydrolysis 
of GTP to GDP, prolonging the active state of RAS and the downstream effector 
signaling that promotes the cancer phenotype. In contrast to the G domain, the C-
terminal end of each RAS isoform is unique, owing to the hypervariable region (residues 
165-188/189). This region is targeted for post-translational modification (farnesylation, 
palmitoylation, geranylgeranylation) and is essential for localizing the RAS proteins to 
the cell membrane (Downward, 2003; Gibbs and Oliff, 1997). 
Although nearly 80% of their protein sequence is conserved, specific RAS genes 
are mutated more often in certain cancers. Roughly 10% of bladder cancers contain 
RAS mutations, a majority of which are in the HRAS isoform. More than 20% of 
melanoma and 11% of acute myeloid leukemia harbor RAS mutations, with NRAS as 
the prevalent mutant RAS gene (Hobbs et al., 2016). While HRAS and NRAS mutations 
are important certain contexts, the KRAS isoform appears to provide a unique and 
essential function (DuPage et al., 2009). Mice deficient in HRAS and NRAS, alone or in 
combination, develop and reproduce normally (Esteban et al., 2001). Whereas, KRAS is 
essential for mouse embryonic development (Johnson et al., 1997; Khalaf et al., 2005; 
Koera et al., 1997). While RAS mutations are found in nearly 25% of all cancers, mutant 
KRAS is the relevant isoform in 85% of these cancers (Figure 1.2). 
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Figure 1.1. The RAS activation cycle in normal cells. Growth factors stimulate receptor tyrosine 
kinases (RTKs), forming a protein complex at the plasma membrane including GRB2 (growth-factor-
receptor bound protein 2), the guanine nucleotide exchange factor (GEF), SOS, and the inactive GDP-
bound RAS. The GDP bound to RAS is displaced by the SOS GEF, and replaced by GTP. This leads to a 
conformational change in the RAS protein, which is now able to bind more than 20 different effectors in its 
activated state. However, this transient activation is terminated once RAS interacts with the GTPase 
activating proteins (GAPs), which accelerate GTP hydrolysis and the return of RAS to its inactive state. 
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Figure 1.2. The four isoforms of the RAS subfamily. HRAS, NRAS, KRAS4A and KRAS4B are 
homologous throughout the G domain (amino acids 1–165). The first 85 amino acids are identical in all 
four proteins and includes the phosphate-binding loop (P loop, amino acids 10–16), which binds GTP, 
and switch I (amino acids 32–38) and II (amino acids 59–67) which regulate binding to Ras regulators 
and effectors. Amino acids 85–165 show roughly 85% sequence identity, while the C-terminal 
hypervariable domain (amino acids 165–188/189) is the least similar and specifies membrane localization 
through post-translational modifications. The majority of somatic RAS mutations found in cancer introduce 
amino-acid substitutions at positions 12, 13 and 61. The pie chart shows the prevalence of the RAS 
isoforms in cancer. Adapted from {Schubbert:2007eq, (Hobbs et al., 2016). 
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Mutations in the KRAS gene are most prevalent in pancreatic, colorectal, and 
lung cancer, which are some of deadliest cancers in the US and worldwide, making 
KRAS the most frequent gain-of-function mutation in cancer (Tan et al., 2015). Animal 
studies have shown the therapeutic potential for inhibiting KRAS in vivo, leading to 
intensive drug discovery efforts focused on inhibiting post-translational modifications, 
effector interaction, or targeting KRAS directly (Baines et al., 2011; Keeton et al., 2017; 
Patricelli et al., 2016; Shima et al., 2015). However, these strategies have not yet 
yielded therapeutic options for patients with KRAS driven cancers. Inhibiting the 
downstream effectors of KRAS has served as a practical alternative in the clinic thus 
far. 
 
1.2. INHIBITING KRAS MUTANT CANCER 
After a decades long effort, attempts to develop drugs able to directly inhibit 
mutant KRAS activity have begun to yield a repertoire of promising molecules, including 
small molecules that irreversibly bind to a common oncogenic mutant, KRAS G12C 
(Ostrem et al., 2013)(Janes et al., 2018). However, more work needed before these 
compounds make it into the clinic. Therefore, utilizing a combination of indirect 
strategies for inhibition of downstream KRAS effectors may hold the most promise in the 
short term (Figure 1.3). 
 
1.2.1. Inhibiting the major effectors of mutant KRAS signaling 
Oncogenic KRAS has the potential to interact with more than 20 effector 
proteins; however, cell lineage, secondary mutations, and energy states ultimately 
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determine which effectors are activated downstream. Recent work by Yuan et al., 
stratified KRAS mutant cancers cells into three major subtypes, including what they 
term the KRAS sybtype, which mainly utilizes RAF to activate MAPK, maintains the 
epithelial phenotype and prefers glycolysis. The RSK subtype relies on RSK instead of 
KRAS, mainly utilizes MTOR, maintains the mesenchymal phenotype and prefers 
oxidative phosphorylation. Finally, the RAL subtype, a smaller subtype, relies on RAL 
and PI3K signaling (Yuan et al., 2018). Below, I will discuss attempts at targeting these 
three major pathways - RAF-MEK-ERK, PI3K-AKT, and the mTOR pathway. 
 
1.2.2. MEK inhibitors 
The importance of the RAF-MEK-ERK pathway downstream of KRAS spurred 
the rapid development of several small-molecule inhibitors targeting RAF or MEK in 
cancer (Zhao and Adjei, 2014). Early studies hypothesized that the inhibition of RAF or 
MEK would produce equally effective outcomes for ERK inactivation. Ultimately, the 
paradoxical induction of RAS dependent RAF dimerization and enhanced ERK 
activation rendered these compounds ineffective in KRAS mutant cancers (Lito et al., 
2013). The utility of MEK inhibitors in KRAS mutant cancers was also undermined by 
sustained ERK activity. These compounds showed no significant benefit in KRAS 
mutant cancers often due to the loss of ERK feedback inhibition and compensatory 
mechanisms that cause the reactivation of ERK (Samatar and Poulikakos, 2014). 
 
1.2.3. ERK inhibitors 
Although the rationale behind the compounds targeting the RAF and MEK 
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kinases was sound, ERK reactivation played a major role in conferring resistance to 
these compounds. Bypassing this issue through direct ERK inhibition could lead to 
much better outcomes. Recent studies have shown BRAF mutant melanoma, resistant 
to RAF and MEK inhibitors, retain sensitivity to ERK1/2-selective pharmacologic 
inhibitors (Hatzivassiliou et al., 2012; Morris et al., 2013). Hayes et al. showed that 
direct pharmacologic inhibition of ERK (Figure 1.3) suppresses the growth in a subset 
of KRAS mutant cells, with long term treatment leading to senescence meditated by 
MYC degradation and p16 reactivation (Hayes et al., 2016). Enhanced basal PI3K-AKT-
mTOR signaling is associated with ERK inhibitor resistance and concurrent treatment 
with PI3K inhibitors lead to synergistic cell death (Hayes et al., 2016), bolstering the 
importance of the PI3K pathway in KRAS mutant cancer cells. 
 
1.2.4. PI3K inhibitors 
Pan-PI3K inhibitors include drugs such as BKM120 (Norvatis), a Class I PI3K 
ATP-competitive inhibitor, and the quinoxaline derivative, XL147 (Exelixis), a Class I 
PI3K inhibitor for the treatment of solid tumors (Liu et al., 2009). Increases in food-
induced plasma insulin levels have been observed with Exelixis; however, sustained 
anticancer activity was achieved in some patients (Shapiro et al., 2014). GDC-0941 
(Piramed/Genentech) displays dramatic antitumor effects in xenograft models (Hoeflich 
et al., 2012) and has been tested in solid tumors and lymphoma. GDC-0941 has also 
been shown to inhibit PI3K activity in the nanomolar range (Liu et al., 2009). 
PI3K isoform-specific inhibitors could potentially allow effective pathway inhibition 
at more tolerable doses with less severe side effects (Courtney et al., 2010). CAL-101 
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(Calistoga), a p110δ-specific inhibitor being studied in refractory hematological cancers, 
shows promising responses in patients (Hoellenriegel et al., 2011; Lannutti et al., 2011). 
Also, low nanomolar concentrations of the Class IA PI3K inhibitor PX-866 
(Oncothyreon) are able to effectively inhibit the pathway in vitro (Ihle et al., 2009). 
 
1.2.5. AKT inhibitors 
AKT is a critical effector downstream of PI3K, which has made this kinase an 
important drug target. There are two main types of AKT inhibitors. ATP mimetics and 
non-catalytic site inhibitors, such as allosteric inhibitors and lipid-based 
phosphatidylinositol (PI) analogs. AKT ATP-competitive inhibitors may lack isoform 
specificity (Liu et al., 2009), such as the pan-Akt inhibitor GSK690693 
(GlaxoSmithKline)(Rhodes et al., 2008). 
The PI analog, Perifosine (Kondapaka et al., 2003), prevents the translocation of 
AKT to the plasma membrane and inhibits AKT activation in response to PI3K. AKT PH 
domain inhibitors, such as PX316 (Pro1X Pharmaceutical) and phosphatidylinositol 
ether lipid analog (PIAs) (National Cancer Institute/Georgetown University) have also 
shown promise in preclinical studies (Gills and Dennis, 2004; Granville et al., 2006). The 
Pan-AKT allosteric inhibitor MK2206, has advanced to phase II clinical trials for 
advanced and metastatic solid tumors (Liu et al., 2009) and showed efficacy in ovarian 
cancer patients (Tolcher et al., 2015). However, similar to Pan-PI3K inhibitors, 
hyperglycemia and skin disorders are observed as side effects. Studies have shown 
non-redundant and opposing roles of different AKT isoforms in various cellular context. 
Therefore, AKT isoform-specific inhibitors may also be worthwhile pursuit. 
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AKT inhibition may be an effective approach in some contexts. However, cancers 
dependent on other PI3K activated effectors such as SGK3 may be less sensitive to 
AKT inhibition (Vasudevan et al., 2009). In addition, long term inhibition of AKT may 
relieve important negative feedback loops and lead to reactivation of PI3K signaling 
(Courtney et al., 2010). 
 
1.2.6. mTOR inhibitors 
The mammalian target of rapamycin (mTOR) is a master regulator of cell growth 
and metabolism. Rapamycin is an immunosuppressant that binds directly to the 
intracellular receptor FK506-binding protein-12 (FKBP12). The Rapamycin-FKBP12 
complex binds to mTORC1 and inhibits its activity (Guertin and Sabatini, 2009). This 
inhibits cell growth, causes cell cycle arrest, and induces cell death through activation of 
autophagy or apoptosis. Rapamycin may also inhibit tumor angiogenesis (Sabatini, 
2006). Rapamycin has been modified to produce derivatives with favorable properties 
(rapalogs) that show more effective antitumor activity. Rapalogs such as Temsirolimus 
(Torisel ,Wyeth), Everolimus (Novartis) and Deforolimus (Merck/Ariad) (Liu et al., 2009) 
were intended to improve on the effects of rapamycin. However, single-agent 
administration of rapalogs usually result in a cytostatic response with no tumor 
regression, effectively stabilizing the disease (Courtney et al., 2010). The efficacy of 
rapalogs may be limited because of the incomplete inhibition of mTORC1. Regardless, 
several rapalogs have been FDA-approved for liquid and solid tumors (McDermott et al., 
2005)(Faivre et al., 2006)(Fruman and Rommel, 2014). 
Second generation ATP-competitive inhibitors targeting both mTORC1 and 
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mTORC2 may hold more promise, since these drugs would suppress mTORC2 
mediated AKT activation in addition to inhibiting mTORC1. However, studies using dual 
mTORC1/mTORC2 inhibitors such as Torin and PP242 appear to show improved 
antitumor effects, not because of the additional mTORC2 inhibition, but because of 
better inhibition of mTORC1 (Feldman et al., 2009; Thoreen et al., 2009). 
 
1.2.7. PI3K and MEK/ERK pathway inhibitors 
As previously discussed, the cross-talk between the PI3K pathway and the RAF-
MEK-ERK signaling pathway plays an important role in cancer cell growth and survival. 
PI3K inhibition can lead to MAPK pathway reactivation. Long-term inhibition of 
mTORC1 can lead to the phosphorylation of ERK, while the inhibition of MEK can 
prevent PTEN membrane recruitment and increase AKT activity (Carracedo et al., 2008; 
Kinkade et al., 2008; Zmajkovicova et al., 2013). These findings highlight the 
therapeutic potential of targeting both these pathways. 
Studies show that PI3K inhibitors and MEK/ERK inhibitors appear to be 
synergistic in cancer models for KRAS-driven lung cancer and NRAS mutant melanoma 
(Engelman et al., 2008; Posch et al., 2013). Inhibition of both pathways could be leading 
to the stabilization and up-regulation of proapoptotic proteins such as BIM, PUMA and 
BAD (Liu et al., 2009).  Although dual PI3K/MAPK inhibition may have therapeutic 
potential, both pathways are essential for normal cellular function and limiting the effects 
of these drugs to cancer cells may be difficult. However, dose optimization or combining 
inhibitors for other effectors of these pathways could help to reduce toxicity. 
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1.2.8. Dual PI3K-mTOR inhibitors 
The similarities between the catalytic domain of PI3K and mTORC allow many 
PI3K or mTORC (1/2) ATP-competitive inhibitors to suppress the activity of both kinases 
(Fry, 2001). One example of a dual PI3K-mTOR inhibitor is SF-1126, a derivative of 
LY294002 being studied in clinical trials. SF-1126 led to tumor stasis in patients with 
minimal toxicity, but not tumor regression (Garlich et al., 2008; Mahadevan et al., 2012). 
BEZ235 also displayed tumor stasis with tolerable side effects in PTEN-deficient cancer 
xenograft studies (Maira et al., 2008). NVP-BGT226 (Novartis) and XL765 (Exelixis) are 
other PI3K-mTORC inhibitors in clinical trials (Courtney et al., 2010). 
Molecules able to inhibit KRAS directly may be an option available to patients 
eventually; however, given the imminent technical hurdles and the probability of drug 
resistance, inhibition of KRAS effectors using the drugs discussed above could be the 
most viable option available to patients for now. 
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Figure 1.3. RAS effector pathways. Growth factors stimulate receptor tyrosine kinases (RTKs) such as 
EGFR and FGFR, which activates a protein complex including GRB2 (growth-factor-receptor bound 
protein 2) and guanine nucleotide exchange factor (GEF) SOS and leads to the activation of KRAS. 
Oncogenic mutations confer resistance to GTPase-activating proteins (GAPs) resulting in constitutive 
activation of KRAS and its effector pathways. The BRAF-MEK-ERK cascade drives proliferation and often 
becomes deregulated in KRAS mutant cancers. KRAS also activates the PI3K-AKT pathway, which 
frequently determines cellular survival. RALGDS, RALGDS-like gene (RGL), RGL2 and TIAM1 are 
exchange factors of Ral and Rac, respectively. Phospholipase D (PLD) is an enzyme that regulates 
vesicle trafficking downstream of Ral, and Rac regulates actin dynamics. KRAS also activates the 
enzyme phospholipase Cε (PLCε), which regulates the protein kinase C (PKC) family and calcium 
signaling. P, phosphate; SCH772984, ERK1/2 inhibitor. Adapted from (Schubbert et al., 2007). 
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1.3. DNA METHYLATION ASSOCIATED WITH ONCOGENIC KRAS 
In addition to aberrant signaling, the expression of mutant KRAS is correlated 
with global differential DNA methylation. Therefore, KRAS-mediated epigenetic 
reprogramming could be an avenue where the survival of KRAS-dependent cancer cells 
may be vulnerable. 
 
1.3.1. Overview of DNA methylation 
In addition to aberrant effector signaling, KRAS mutant cancer cells also undergo 
genome-scale epigenetic changes including DNA methylation. In genomic DNA, 
cytosine residues in CpG sequences are methylated at the fifth position (5-
methylcytosine, 5mC) by DNA methyltransferases (DNMTs) (Deaton and Bird, 2011). 
DNMT1, maintains the methylation state during cell division, and shows a preference for 
hemi-methylated DNA. Whereas, DNMT3a and DNMT3b function as de novo 
methyltranferases and are responsible for generating brand new methylation patterns 
(Klose and Bird, 2006). CpG methylation can have effects on chromatin structure and 
regulate gene expression (Baylin, 2005). The mechanism by which CpG methylation 
represses gene expression is not fully understood; however, studies suggest that CpGs 
block transcription factor binding at promoter regions, recruit heterochromatin factors, or 
recruit histone deacetylases (HDACs) via methyl-CpG-binding domain proteins (Baylin, 
2005). CpG methylation plays an important role in normal development and is more 
stably maintained than chromatin modifications. X chromosome inactivation, gene 
imprinting, transposons, all which require long-term silencing, utilize this epigenetic 
mechanism (Horii and Hatada, 2016). However, CpG methylation is reversible, and can 
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be dynamically regulated. The Tet hydroxylase proteins are able to catalyze the 
hydroxylation of 5mC to 5-hydroxymethylcytosine (5hmC), subsequently leading to the 
formation of 5-formylcytosine (5fC) and 5-carboxylcytosine, which are both ultimately 
removed by thymine DNA glycosylase and base excision repair (He et al., 2011). 
 
1.3.2. DNA methylation in KRAS mutant cells 
Global DNA hypomethylation and focal hypermethylation at CpG islands (CpGI) 
have become hallmarks of cancer (Figure 1.4) (Belinsky, 2004; Jones and Baylin, 2002; 
Sharma et al., 2010). Moreover, oncogenic KRAS expression has specifically been 
shown to induce aberrant DNA methylation, promoting hypomethylation across the 
genome while silencing key tumor suppressors through hypermethylation (Gazin et al., 
2007; Serra et al., 2014). This KRAS-associated differential DNA methylation could 
have a significant impact on promoter regulation across the genome and lead to 
important oncogenic transcriptional changes. Discovering an essential and predictable 
epigenetic response to mutant KRAS expression would reveal other potential anti-
cancer targets. However, in a recent study using fibroblasts, Xie et al. found that HRAS-
transformed cells show methylation patterns diverging dramatically compared with the 
reproducible methylation pattern of senescence (Xie et al., 2018). The authors suggest 
that transformation involves stochastic epigenetic patterns from which malignant cells 
may evolve. Ultimately, a better understanding of the DNA methylation events 
associated with oncogenic KRAS expression could enhance therapeutic approaches for 
KRAS-driven cancers and provide a platform for understanding the intrinsic 
heterogeneous nature of these cancers.  
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Figure 1.4. Diagram showing the methylation at CpG centric and gene centric regions. The DNA 
methylation marks, 5-methylcytosine (5mC) are deposited by one of the three DNA methyltransferases 
(DNMT1, DNMT3a/b). Promoter hypermethylation is generally correlated with reduced mRNA expression, 
and hypomethylation with increased expression. However, the relationship between promoter methylation 
and gene transcription requires validation, since the converse relationship is observed occasionally; as 
well as, the absence of any effect on transcription. Promoter region, TSS1500 or TSS200, 1500 or 200 nt 
upstream of the transcription start site; Shelf, 2 to 4 kb from CpG island; Shore, <2 kb from CpG island. 
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1.4. NF-κB SIGNALING IN KRAS-DRIVEN CANCER 
In addition to regulating immune responses, the NF-κB family of transcription 
factors also promotes cellular proliferation and survival. NF-κB and its activating kinase, 
IKK, have become appealing therapeutic targets because of their critical roles in the 
progression of many diseases including chronic inflammation and cancer. Here we 
discuss the conditions that lead to pathway activation, the effects of constitutive 
activation, and some of the strategies used to inhibit NF-κB signaling. 
 
1.4.1. IKK and NF-κB signaling 
Initially thought to be a B-cell-specific transcription factor (Sen and Baltimore, 
1986), nuclear factor of κB (NF-κB) plays a crucial and evolutionarily conserved role in 
immunity (Ghosh et al., 1998). However, since its discovery in 1986 (Sen and Baltimore, 
1986), NF-κB expression has been found in virtually every cell type. In the absence of 
inducing stimuli, it is inactivated through interaction with inhibitor proteins of the IκB 
family. Upon activation, NF-κB is involved in the regulation of genes that impact not only 
immune responses, but also cell proliferation, survival, and differentiation. 
The NF-κB family of transcription factors consists of five structurally-related 
protein subunits that share affinity for the κB DNA sequence motif (Ghosh et al., 1998; 
Kunsch et al., 1992; Pierce et al., 1988). This family of proteins can be divided into two 
classes; the NF-κB proteins (p105/p50 or NFKB1 and p100/p52 or NFKB2) and the Rel 
proteins (c-Rel, RelB, and RelA/p65) (Gilmore, 1999a). Through proteasome-mediated 
proteolysis, p105 and p100 are processed into the shorter DNA-binding subunits called 
p50 and p52, respectively (Betts and Nabel, 1996; Fan and Maniatis, 1991). The Rel 
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proteins are distinguished by C-terminal transcriptional activation domains (TAD) 
(Schmitz and Baeuerle, 1991), while all five NF-κB/Rel subunits contain the N-terminal 
Rel homology domain (RHD), essential for DNA binding, dimerization, Inhibitor of κB 
(IκB) interaction, and nuclear localization (Chen and Ghosh, 1999; Urban and Baeuerle, 
1990) (Figure 1.5). 
The canonical NF-κB transcription factor is a dimer composed of a p50 and 
RelA/p65 subunit, which largely resides in the cytoplasm as part of a latent complex 
with IκBα under basal conditions (Baeuerle and Baltimore, 1988b; 1988a). This highly 
inducible pathway is activated by intracellular or extracellular signals such as tumor 
necrosis factor alpha or TNF-α, interleukin-1 or IL-1, lipopolysaccharide (LPS), viral 
double stranded RNA, and ionizing radiation (Brach et al., 1991; Chow et al., 1999; Gil 
et al., 2000; Hoshino et al., 1999; Osborn et al., 1989) (Figure 1.6). Pathway activation 
leads to induction of the Inhibitor of κB kinase (IKK) complex comprised of the two 
catalytic subunits IKKα and IKKβ, and one scaffold subunit called nuclear factor κB 
essential modulator (NEMO) or IKKγ (Chen et al., 1996; DiDonato et al., 1997; Mercurio 
et al., 1997; Rothwarf et al., 1998; Yamaoka et al., 1998). IκBα is phosphorylated at 
serine 32 and 36 by the IKK complex (Brown et al., 1995; Traenckner et al., 1995; 
Whiteside et al., 1995), polyubiquitinated (Chen et al., 1995; DiDonato et al., 1996; 
Scherer et al., 1995) and degraded by the proteasome (Miyamoto et al., 1994; 
Whiteside et al., 1995). The degradation of IκBα consequently frees the canonical NF-
κB dimer, p50-RelA/p65, to translocate into the nucleus and activate gene transcription 
(Antonaki et al., 2011; Miyamoto et al., 1994). 
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Although the canonical NF-κB pathway has been more extensively studied, the 
noncanonical pathway is important within certain contexts (Dejardin, 2006). Activation of 
the “alternative” pathway begins with the induction of TNF receptor (TNFR) family 
members such as lymphotoxin-beta receptor or LTβR (Dejardin et al., 2002), receptor of 
B cell-activating factor belonging to the TNF family or BAFF-R (Claudio et al., 2002; 
Kayagaki et al., 2002), receptor activator of NF-κB (RANK) (Novack et al., 2003) and 
cluster of differentiation 40 (CD40) (Coope et al., 2002). Upon receptor activation, TNF 
receptor associated factor (TRAF) proteins mediate the activity of NF-κB inducing 
kinase (NIK) (Liao et al., 2004), which activates an IKKα homodimer (Ling et al., 1998; 
Senftleben et al., 2001) leading to p100 processing into the active p52 subunit (Xiao et 
al., 2004). Ultimately, processing of p100 results in the generation of the noncanonical 
transcription factor, a p52-RelB dimer, which is then able to move onto available κB 
DNA-binding sites and control expression of its associated genes (Bonizzi et al., 2004). 
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Figure 1.5. Structure of the human NF-κB/Rel, IκB, and IKK proteins. The NF-κB/Rel family of 
proteins consists of five members containing the characteristic Rel homology domain (RHD). These 
protein subunits are able to stably interact with each other via the RHD to form various context-dependent 
dimers (Perkins, 2007). The RHD is also essential for DNA binding, Inhibitor of κB (IκB) interaction, and 
nuclear localization (Chen and Ghosh, 1999; Urban and Baeuerle, 1990). RelA/p65, c-Rel and RelB 
contain a transcriptional activation domain (TAD), and so NF-κB transcription factors containing one of 
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these Rel subunits usually function to activate gene transcription (Oeckinghaus and Ghosh, 2009). The 
p100 and p105 precursor proteins contain a C-terminal ankyrin repeat domain (ARD) that is proteolytically 
cleaved away to produce the active subunits p52 and p50, respectively. The presumed cleavage sites are 
denoted by the arrows (Hayden and Ghosh, 2004; Lin and Kobayashi, 2003). Processing of p100 is 
regulated by the NF-κB-inducing kinase (NIK) and IKKα, which induce site-specific phosphorylation and 
ubiquitination (Xiao et al., 2004). The C-terminus of the p105 precursor is selectively degraded by the 20S 
proteasome leading to p50 generation in an ubiquitin-independent manner. The glycine rich region (GRR) 
prevents the complete degradation of the precursors (Moorthy et al., 2006), while a processing-inhibitory 
domain (PID) (not shown) functions to suppress processing altogether (Cohen et al., 2009; Xiao et al., 
2001). Both precursor proteins harbor a death domain (DD) that is required for signal-induced proteolysis 
(Beinke et al., 2002; Xiao et al., 2001). 
The ankyrin repeat domain (ARD) is the characteristic domain of the IκB proteins including IκBα, 
IκBβ, IκBγ, IκBε and Bcl3. In fact, the p100 and p105 molecules themselves may act as inhibitors of NF-
κB before their ARD is cleaved away. The ARD mediates interaction with the NF-κB/Rel proteins 
obstructing their nuclear localization signal (NLS) within the RHD of the Rel proteins and restricting 
nuclear translocation. Phosphorylation of two N-terminal serine residues (SS) of IκB triggers 
polyubiquitination and proteasome-mediated degradation. Bcl3 is considered an unusual IκB, which is 
inducible, restricted to the nucleus, and is not degraded upon pathway activation. It also contains ankyrin 
repeats, but does not always act as a repressor. Due to its TAD, when Bcl3 assembles with p50 or p52, 
these new complexes can activate transcription. Two other unusual IκBs are IκBζ and IκBNS (not shown), 
which can activate IL-6 and IL-2, respectively (Siebenlist et al., 2005). 
The IκB kinase (IKK) complex consists of the catalytic subunits IKKα and IKKβ and the regulatory 
subunit called the NF-κB essential modifier (NEMO, also called IKKγ). The kinase domain of IKKε shares 
27% identity with IKKα and 24% with IKKβ. TBK1 shares 65% similarity to IKKε. NEMO contains several 
domains that are crucial for its function as a regulatory subunit of the canonical IKK complex. The N-
terminal coiled-coil domain (CC1) interacts with IKKα and IKKβ (Marienfeld et al., 2006). The other coiled-
coil region (CC2) together with the leucine zipper (LZ) forms the ubiquitin-binding domain. Finally, the C-
terminal zinc-finger (ZNF) region that may be involved in substrate interactions (Schröfelbauer et al., 
2012). IκB, inhibitor of NF-κB; SS, conserved serines in IκB; ULD, Ubiquitin-like domain; HLH, helix-loop-
helix; NBD, NEMO-binding domain; Bcl3, B-cell lymphoma 3. 
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Figure 1.6. The canonical and noncanonical NF-κB pathways. (Left) The canonical pathway is 
activated by TNF-α, IL-1, LPS, CD40 ligand (CD40L), lymphotoxin α/β (LT α/β) and BAFF. The IKK 
complex phosphorylates IκBα and induces its degradation, leading to activation of innate immunity, 
inflammation, inhibition of apoptosis, and/or proliferation. (Right) The noncanonical pathway is activated 
by LT α/β, CD40L and BAFF and depends on NIK and IKK-α homodimers to induce processing of p100 
and nuclear translocation of p52-RelB dimers. This pathway is crucial for secondary lymphoid organ 
development, maturation of B cells and adaptive humoral immunity, but can also have proliferative and 
anti-apoptotic effects. IκB, inhibitor of NF-κB; IKK, IκB kinase; IL, interleukin; LPS, lipopolysaccharide; 
TNF, tumor-necrosis factor. Modified from (Karin et al., 2004). 
  
 23 
1.4.2. NF-κB Target Gene Specificity 
The inducible family of NF-κB transcription factors regulates a broad spectrum of 
target genes involved in a number of critical cellular processes (Gaur and Aggarwal, 
2003; O'Neill and Kaltschmidt, 1997; Pahl, 1999). In order to achieve specificity cells 
utilize a number of mechanisms to regulate the transcriptional response downstream of 
NF-κB pathway activation (Smale, 2011). The NF-κB subunits can form various 
combinations of distinct homodimers or heterodimers with each of the two subunits 
contacting one half of the κB DNA-binding site (Baldwin, 1996; Siebenlist et al., 1994). 
Slight alterations within a κB consensus site can therefore result in different affinities for 
specific dimer combinations (Kunsch et al., 1992). Moreover, composition of the 
activated dimeric complex is determined by the particular activating stimulus as 
observed in noncanonical pathway activation (Sun, 2011). Target gene specificity can 
also be achieved through regulation of access to κB sites via chromatin modifications 
(De Santa et al., 2009; 2007; Levy et al., 2011; Saccani and Natoli, 2002; van Essen et 
al., 2010). Epigenetic changes during development, reprogramming and differentiation 
can create cell type-specific open or closed regions of chromatin, which will determine 
the κB sites available for transcription factor binding (Ramirez-Carrozzi et al., 2009). 
Different stimuli can affect the duration of NF-κB activation leading to stimulus-specific 
activation kinetics (Ashall et al., 2009; Hoffmann et al., 2006; Hoffmann and Baltimore, 
2006; Lee and Covert, 2010; Paszek et al., 2010; Sen and Smale, 2010; Tay et al., 
2010; Wang et al., 2011). Target gene expression can depend on stimulus-dependent 
post-translational modifications of the NF-κB subunits which can reduce autoinhibition 
or support interaction with cofactors required for efficient induction (Oeckinghaus et al., 
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2011; Perkins, 2006). These and other mechanisms for selective gene induction confer 
context-dependent specificity upon NF-κB activation, despite the pathway’s broad range 
of targets. 
 
1.4.3. NF-κB in Inflammation, Survival and Proliferation 
The NF-κB pathway has been well established as a critical regulator of immunity. 
It is one of the few pathways responsible for the inducible expression of genes like 
ICAM, IL-1, IL-6, IL-8, and TNF-α that are crucial for the acute phase response during 
inflammation (Ghosh et al., 1998). Cytokines like IL-1 and TNF-α can activate the 
pathway, potentially leading to a deleterious feed-forward loop (Ling et al., 2012; Yang 
et al., 2009). However, the NF-κB transcription factor also upregulates IκBα expression 
thereby maintaining transient induction via the appropriate inhibitory feedback (Brown et 
al., 1993; Chiao et al., 1994; Scott et al., 1993; Sun et al., 1993). Long non-coding 
RNAs (Liu et al., 2015) and ubiquitin-editing enzymes such as A20 (Ruland, 2011) can 
also act as negative feedback regulators. The inextricable relationship between NF-κB 
and inflammation has made the pathway an obvious culprit in chronic inflammatory 
diseases (Lawrence, 2009). Anti-inflammatory drugs such as aspirin, dexamethasone, 
and prednisone can indeed inhibit pathway activation (Auphan et al., 1995; Kopp and 
Ghosh, 1994; Ray and Prefontaine, 1994; Scheinman et al., 1995; Yamamoto and 
Gaynor, 2001), placing NF-κB as a prime target of therapies against inflammatory 
disease. 
In addition to regulating inflammatory cytokines, NF-κB also regulates important 
genes associated with cell survival, such as cIAP1/2, Bcl-2, and Bcl-xL (Piva et al., 
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2006). The role of NF-κB in cell survival was made clear in the November issue of 
Science in 1996 (Beg and Baltimore, 1996; Van Antwerp et al., 1996; Wang et al., 
1996). A series of studies lead by Baltimore, Verma, and our group showed that the 
loss, inhibition, or lack of NF-κB activation significantly increased stimulus-induced cell 
death. Wang et al. found that the pathway is activated by ionizing radiation and some 
chemotherapeutic compounds and that NF-κB could be reducing the efficacy of cancer 
therapies by promoting cell survival (Wang et al., 1996). 
NF-κB influences cell proliferation via its regulation of cyclin D1 (Guttridge et al., 
1999; Joyce et al., 2001) and growth factors (Oeckinghaus and Ghosh, 2009). In B cells 
the pathway promotes proliferation and differentiation, indispensible processes in 
mounting an adaptive immune response (Ghosh et al., 1998). However, because NF-κB 
and IKK proteins are expressed ubiquitously, aberrant cells of almost any kind can 
hijack this proliferative signal and, coupled with its pro-survival target genes, drive 
uncontrolled growth leading to diseases such as cancer (Ben-Neriah and Karin, 2011). 
 
1.4.4. IKK and NF-κB signaling in disease 
The NF-κB pathways have been functionally implicated in a variety of diseases 
including muscular dystrophy (Acharyya et al., 2007; Li et al., 2008), asthma (Barnes 
and Adcock, 1997), bone diseases (Boyce et al., 2010), age-related diseases (Salminen 
et al., 2008) and a number of cancers (Ben-Neriah and Karin, 2011; Gilmore and 
Garbati, 2011). The crucial role of NF-κB in such ailments has led to promising 
outcomes in studies using specific inhibitors against the pathway. An early example of 
this was in an animal model of rheumatoid arthritis, where intraarticular administration of 
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NF-κB decoys prevented the recurrence of streptococcal cell wall-induced arthritis in 
rats (Miagkov et al., 1998). In another model of rheumatoid arthritis the allosteric IKK 
inhibitor BMS-345541 was used to treat collagen-induced arthritis in mice. When 
administered as a prophylactic (before disease), BMS-345541 was effective, in a dose-
dependent manner, in reducing the incidence and clinical signs of disease. Histologic 
evaluation of the joints showed that the IKK inhibitor blocked both inflammation and joint 
destruction. Dose-dependent reduction in disease severity was also observed with the 
therapeutic (after disease) dosing regimen, with the 100 mg/kg dose resulting in 
resolution of disease (McIntyre et al., 2003). Since then, more than a decade of 
research has explored mechanisms to inhibit the NF-κB pathway in a number of 
different settings. More recently, efforts have been directed at blocking IKK and NF-κB 
in cancer. 
NF-κB was first implicated in cancer when the c-Rel subunit was identified as the 
homolog of v-REL (Kieran et al., 1990; Wilhelmsen et al., 1984), the transforming gene 
of the avian REL retrovirus strain T (REV-T) (Gilmore, 1999b). The c-Rel subunit has 
since been found to play important roles in several different cancers including 
lymphoma, breast and pancreatic cancer (Gilmore and Gerondakis, 2011; Hunter et al., 
2016). The RelA/p65 subunit is required for transformation induced by oncogenes such 
as BCR-ABL (Reuther et al., 1998) and RAS (Finco et al., 1997). Inhibiting the 
canonical pathway by expressing the dominant-negative form of IκBα (Meylan et al., 
2009) or via gene knockouts of RelA/p65 (Bassères et al., 2010) and IKKβ (Xia et al., 
2012) block tumor progression in KRAS-driven murine cancer models. 
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More recent evidence has shown that both canonical and noncanonical NF-κB 
pathways can promote oncogenesis, potentially through control of tumor initiating cells 
(TICs) (Bang et al., 2013; Kendellen et al., 2014; Rinkenbaugh et al., 2016). In ER-
negative basal-like breast cancer cells, EZH2 interacts with RelA/p65 and RelB to 
confer constitutive activation of NF-κB target gene expression independent of its histone 
methyltransferase activity. This appears to be context-dependent, since EZH2 
represses NF-κB target genes in ER-positive luminal-like breast cancer cells (Lee et al., 
2011). Recently, our group has shown that EZH2, through a methyltransferase-
independent mechanism, promotes the transcriptional activation of RelB to drive self-
renewal and the tumor initiating cell phenotype of triple-negative breast cancer cells 
(Lawrence and Baldwin, 2016). 
RelA/p65 has also been shown to interact with signal transducer and activator 3 
(STAT3) in cancer (Fan et al., 2013). Association with STAT3 can prolong NF-κB 
nuclear retention by altering p300-mediated RelA/p65 acetylation (Lee et al., 2009). 
Nuclear RelA/p65-STAT3 interaction is significantly elevated by radiation in human 
glioma xenograft cell lines. Radiation, part of the standard treatment in glioblastoma 
multiforme (GBM), also increases migration, invasion, and the levels of intercellular 
adhesion molecule-1 (ICAM-1) (Kesanakurti et al., 2013). Glioma cancer stem cells 
(CSCs) also show nuclear RelA/p65-STAT3 interaction, upregulation of NF-κB and 
STAT3 target genes, and sensitivity to inhibitors of STAT3 and NF-κB (Garner et al., 
2013; Rinkenbaugh et al., 2016). Therefore, STAT3 appears to cooperate with NF-κB to 
promote the progression of certain cancers (Grivennikov and Karin, 2010). However, in 
some breast cancer cells, depending on the methylation at the miR-146b promoter, 
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STAT3 induces the expression of this miRNA, a negative regulator of NF-κB (Xiang et 
al., 2014). Innate immune cells lacking STAT3 also display elevated NF-κB activity in 
response to LPS and RANKL (Zhang et al., 2014). Together these findings suggest that 
STAT3 is an important and context-dependent modulator of inflammation and NF-κB 
activity. 
Due to its ability to self-regulate, dysregulation of the NF-κB pathway can initiate 
perpetual activation in cancer cells (Baldwin, 2001). Constitutive activation of Kras and 
IKK/NF-κB are signature alterations in pancreatic ductal adenocarcinoma (PDAC). In a 
mouse model of PDAC, KrasG12D-activated AP-1 induces IL-1α, which activates 
RelA/p65 and its target genes IL-1α and p62. This initiates IL-1α and p62 feed-forward 
loops that sustain NF-κB activity. Kras mutation correlates with NF-κB activity, IL-1α 
overexpression, and poor survival in PDAC patients (Ling et al., 2012). 
Interest in the noncanonical NF-κB pathway continues to grow as its role in 
cancer becomes more and more apparent. Polyps isolated from an experimental colitis 
mouse model deficient for a protein called NLRP12 show increased expression of 
cancer-associated target genes, including Cxcl13 and Cxcl12. Nlrp12 knockout mice 
showed elevated noncanonical NF-κB signaling and were highly susceptible to 
gastrointestinal inflammation and colitis-associated colon cancer (Allen et al., 2012). 
Inhibition of immunosuppressive myeloid-derived suppressor cells (MDSCs) is important 
for the efficacy of cancer immunotherapy. A subset of MDSC in breast cancer can 
inhibit T cell function through STAT3-dependent IDO upregulation. Increased NIK levels 
and RelB-p52 binding to the IDO promoter accompany increased STAT3 activation in 
these cells, while the STAT3 inhibitor JSI-124 and NIK knockdown are able to inhibit 
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IDO expression (Yu et al., 2014). NIK signaling is also important in pancreatic cancer 
(Döppler et al., 2013; Nishina et al., 2009; Prabhu et al., 2014; Storz, 2013). 
The efficacy of an inhibitor will rely on the cell type-dependent and stimulus-
specific responses of the NF-κB pathways. Selective and reliable targeting of IKK is 
typified by work done in melanoma by Yang et al. IKK inhibition in melanoma cells leads 
to apoptosis, likely due to the NF-κB-dependent regulation of the programmed cell 
death machinery. Inhibition of constitutive IKK activity by BMS-345541 reduced NF-κB 
activity and melanoma cell survival in vitro and in vivo. The effect of BMS-345541 on 
tumor cell growth was through mitochondria-mediated apoptosis, based on the release 
of apoptosis-inducing factor (AIF), dissipation of mitochondrial membrane potential, and 
the reduced ratio of B cell lymphoma gene-2 (Bcl-2)/Bcl-associated X protein (Bax) in 
mitochondria (Yang et al., 2006). 
Both IKKα and IKKβ have been linked to oncogenic pathways that are NF-κB-
independent. For instance, IKKα was shown by our group to promote both mTORC1 
and mTORC2 signaling (Dan et al., 2016; 2014). IKKβ activates mTORC1 downstream 
of TNFα signaling via phosphorylation and suppression of TSC1 (Lee et al., 2007). IKKβ 
also phosphorylates FOXO3a to promote oncogenesis (Hu et al., 2004). Finally, Karin 
and colleagues showed that IKKα phosphorylates the CDK inhibitor p27 in HER2+ brain 
cancer to promote removal from the nucleus and drive tumor initiating cells (Zhang et 
al., 2013). 
Taken together, an important role for the IKK/NF-κB pathway emerges in many 
different types of cancer. The field has made great strides in developing inhibitors of 
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IKK/NF-κB activity. However, the quest to reliably and selectively inhibit the NF-κB 
pathway in all contexts continues. 
 
1.4.5. Noncanonical NF-κB in KRAS-driven cancer 
The majority of research related to the NF-κB pathway, is focused on the 
canonical pathway and the RELA/p65 transcription factor. However, the noncanonical 
NF-κB pathway promotes cell survival in many different cancers (Tegowski and 
Baldwin, 2018). A recent study by Hamidi et al., found that Nupr1 (Nuclear protein 1) 
protects pancreatic cells from stress-induced death by inhibiting apoptosis through a 
pathway dependent on the noncanonical NF-κB transcription factor, RELB. Pancreas-
specific deletion of RELB in a KRAS G12D background delays PanIN development, and 
expression of NUPR1, RELB, and IER3 correlates with a poor prognosis in patients with 
pancreatic ductal adenocarcinoma (PDAC) (Hamidi et al., 2012). Cumulatively, these 
results suggest that RELB, along with NUPR1 and IER3, is important for oncogenic 
KRAS G12D-dependent transformation of the pancreas. 
Errors in chromosome segregation, a hallmark of cancer, generate micronuclei, 
which spill genomic DNA into the cytosol. This leads to the activation of the cGAS–
STING (cyclic GMP-AMP synthase-stimulator of interferon genes) cytosolic DNA-
sensing pathway and downstream noncanonical NF-κB signaling (Bakhoum et al., 
2018). Cytosolic DNA can activate the noncanonical NF-κB pathway in a STING-
dependent and TBK1-independent manner (Abe and Barber, 2014). Cells with high 
levels of chromosome instability display high ratios of p52 and phosphorylated p100, 
and reduced levels of the noncanonical pathway inhibitor TRAF2 (Sun, 2010). Bakhoum 
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et al. also showed that STING depletion, reduces RELN nuclear locqalization and 
downregulation of EMT (Bakhoum et al., 2018). In addition, they found that STING and 
downstream noncanonical NF-κB activity mediate metastasis in a tumor cell-
autonomous manner, as evidenced by reduction in metastatic dissemination, lifespan 
extension, and reduction in in vitro and in vivo invasion of cells with chromosome 
instability depleted of STING, RELB, or p100 (encoded by NFKB2). 
Enhanced RELB activity in human lung adenocarcinoma has been previously 
reported (Giopanou et al., 2015) and suggests important roles for noncanonical NF-κB 
signaling in KRAS-driven cancer. Importantly, IKKα, the main upstream activating 
kinase of RELB, has been identified as the critical kinase for oncogenic NF-κB 
activation of KRAS-mutant lung adenocarcinoma (Vreka et al., 2018). IKKα deletion 
displays protective effects in four different mouse models of combined KRAS-driven 
carcinogenesis and IKK depletion from the respiratory epithelium. In addition, 17-
DMAG, a potent HSP90 inhibitor, protects mice from KRAS G12D driven lung 
adenocarcinoma when given early (preventive treatment) or late (regression trial), while 
the IKKβ blocker TPCA-1, did not. Although 17-DMAG likely suppresses a spectrum of 
targets broader than IKKα and IKKβ, inclusively targeting IKKα utilizing even this 
nonspecific approach provided superior overall effects in reducing tumor burden in this 
model compared with IKKβ-specific inhibition (Vreka et al., 2018). In addition, recent 
evidence indicates that IKKβ might not be the only kinase responsible for oncogenic NF-
κB activation of KRAS-mutant lung adenocarcinoma (Van Waes, 2011). TBK1 has 
emerged as a KRAS addiction partner and as a mediator of EGFR-inhibitor resistance, 
while IKKε promotes tumorigenesis together with TBK1 (Zhu et al., 2014). The studies 
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exploring the role of IKKα depletion together with IKKβ in lung cancer cells in vitro show 
that both kinases to be important (Bassères et al., 2014). 
 
1.4.6. Targeting IKK and NF-κB Signaling 
Numerous inhibitors of IKK and NF-κB activity have been reported and these 
have been reviewed extensively (Gilmore and Herscovitch, 2006; Gilmore and Garbati, 
2011; Karin et al., 2004). Here we will provide an updated perspective of the general 
strategies for pathway inhibition and discuss therapeutic uses of IKK/NF-κB inhibitors. 
Some natural products including certain antioxidants and thiol-reactive 
compounds can be classified as inhibitors of IKK/NF-κB activity (Folmer et al., 2008; 
Khanna et al., 2007; Ríos et al., 2009). The natural products epigallocatechin gallate 
(EGCG, found in green tea) and resveratrol (found in grapes, berries, peanuts, etc.) are 
able to inhibit NF-κB activity, which may partly explain the anti-inflammatory and 
anticancer properties of these compounds (Bhardwaj et al., 2007; Park et al., 2012; Ren 
et al., 2013; Syed et al., 2007). Extensive data indicate that the natural product 
curcumin also has anti-inflammatory and anticancer properties, partly through its ability 
to suppress NF-κB activation (Deguchi, 2015). Data indicate that curcumin induces S-
nitrosylation of IKKβ to block its activity (Kao et al., 2016). Triptolide, a diterpenoid 
epoxide endogenously produced by the thunder god vine (Tripterygium wilfordii) (Ziaei 
and Halaby, 2016) and several other natural products with known anti-inflammatory 
properties have been shown to suppress NF-κB activation (Gilmore and Herscovitch, 
2006). 
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Biomolecular and peptide IKK/NF-κB inhibitors include decoy oligonucleotides 
containing the κB site, ribozymes, siRNAs, the IκB super-repressor, dominant-negative 
molecules, and interfering peptides like NBD (Habineza Ndikuyeze et al., 2014). 
Synthetic, small molecule inhibitors are usually designed against the IKK complex 
(Edwards et al., 2009; Karin et al., 2004; Lee and Hung, 2008) because of its upstream 
regulatory role and the clinical success that other protein kinase inhibitors have shown. 
These inhibitors (natural, biomolecular, and synthetic drugs) can target the pathway at 
different stages in the multi-step activation of NF-κB. The following sections have been 
divided based on the steps of activation that are commonly targeted (Figure 1.7). 
 
1.4.6.1. Receptor Inhibition 
The TNF receptor family members upon ligand binding activate the NF-κB 
pathway; therefore, inhibiting receptor engagement prevents signal transduction. 
Research into blocking this stage of pathway activation has spawned anti-TNF 
antibodies. These inhibitors include monoclonal antibodies such as infliximab 
(Remicade) (Liu et al., 2016; Tsang et al., 2016), adalimumab (Humira) (Asahina et al., 
2016; Colombel et al., 2007; Yokoyama et al., 2016), golimumab (Simponi) (Sandborn 
et al., 2014a; 2014b), certolizumab pegol (Cimzia) (Mittal and Raychaudhuri, 2010; 
Patel and Moreland, 2010; Sandborn et al., 2007), and a circulating receptor fusion 
protein called etanercept (Enbrel) (Bozkurt et al., 2001; Mease et al., 2000; Taylor, 
2010; van Schie et al., 2016). This strategy has been one of the more clinically 
successful efforts and is used to counteract the effects of TNF in a number of chronic 
 34 
inflammatory diseases (Taylor and Feldmann, 2009). Despite numerous side effects 
(Scheinfeld, 2004), anti-TNF antibodies provide significant clinical benefit. 
 
1.4.6.2. Adaptor Inhibition as a Potential Strategy 
Once an NF-κB-activating transmembrane receptor is engaged by its ligand, its 
associated adaptors and signal transducing complexes are recruited to the plasma 
membrane. These intracellular complexes include the TRAF proteins, which are 
required for IKK activation. The TRAF proteins function as E3 ligases and form a 
complex with the E2 ubiquitin-conjugating UBC13 and UVE1A proteins (Skaug et al., 
2009; Wang et al., 2012). NEMO interacts with the K63 ubiquitin oligomers deposited by 
the TRAF containing complex, which leads to activation of the canonical IKK complex 
(Clark et al., 2013). Loss-of-function studies have emphasized the crucial role for these 
ubiquitinating adaptor proteins in NF-κB signal transduction (Chen, 2005). Moreover, 
mutations in the ubiquitin-editing enzymes A20 and CYLD, which usually function as 
inhibitors of NF-κB activity, have been found in human cancers (Courtois and Gilmore, 
2006). Even though ubiquitinase inhibitors have been discovered (Tsukamoto et al., 
2008), the TRAF and UBC proteins are involved in too many different signaling 
pathways to be considered as promising targets for specific inhibition of NF-κB activity. 
 
1.4.6.3. IKK Inhibition 
IκB kinase (IKK) has been the main focus in the effort to target the NF-κB 
pathway with numerous small molecules specifically designed to inhibit its activity 
(Gilmore and Herscovitch, 2006). Pharmaceutical companies have developed a number 
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of synthetic compounds capable of competing for the ATP-binding pocket of IKK. Some 
of these ATP analogs are highly selective, such as SPC-839, which has 200-fold higher 
affinity for IKKβ than IKKα (Karin et al., 2004; Lee and Hung, 2008). Bay 65-1942 
(Compound A) is another highly selective ATP-competitive IKKβ inhibitor that shows 
broad anti-inflammatory and anticancer activity (Bassères et al., 2010; Ziegelbauer et 
al., 2005). Some studies indicate that β-carboline alkaloid, a natural product widely 
expressed in plants, may be an ATP analog inhibitor of IKK activity (Yoon et al., 2005). 
Allosteric IKK inhibition can also be very effective. BMS-345541 is a selective IKK 
inhibitor that binds similar allosteric sites on IKKβ and IKKα and serves as an effective 
tool compound in studies of inflammation and cancer (Burke et al., 2003; McIntyre et al., 
2003; Yang et al., 2006). 
Thiol-reactive compounds like parthenolide, arsenite, and certain epoxyquinoids 
can interact with the thiol group of Cys179 in the activation loop of IKKβ and block its 
activity (Kapahi et al., 2000; Liang et al., 2003; 2006). Epoxyquinone A monomer (EqM), 
a synthetic derivative of the natural product epoxyquinol A, is a potent inhibitor of TNF-
α-induced NF-κB activation. EqM inhibits IκBα phosphorylation and degradation by 
targeting Cys179 of IKKβ. EqM may even inhibit DNA binding of the canonical 
transcription factor via interaction with the thiol group of Cys38 on the RelA/p65 subunit. 
Finally, inhibition of the NF-κB pathway by EqM significantly reduces growth of human 
leukemia, kidney, and colon cancer cell lines (Liang et al., 2006). Withaferin A, a natural 
product found in the Ayurvedic plant Withania somnifera, has also been shown to inhibit 
NF-κB and inflammation in vitro and in vivo through its interaction with Cys179 
(Heyninck et al., 2014). The Ser177 and Ser181 residues of IKKβ are part of the kinase 
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activation loop and must be phosphorylated for IKKβ to be activated in response to 
upstream signals (Perkins, 2006; Scheidereit, 2006). The fact that these important 
serine residues are adjacent to Cys179 resulted in researchers assuming that these 
thiol-reactive compounds simply worked through steric hindrance. However, the 
mechanism proved to be more complicated, when some thiol-reactive compounds were 
able to inhibit the constitutively active S171/181E IKKβ mutant (Kwok et al., 2001; Liang 
et al., 2003). 
Dominant-negative mutants of the kinases in the NF-κB pathway can limit 
activation. Dominant-negative kinases can contain a mutated ATP-binding site, a 
mutated kinase activation loop, or a deleted kinase domain (Scheidereit, 2006). IKKβ, 
IKKα, and NIK mutants exhibit stimulus-specific effects, due to their distinct roles in the 
canonical and noncanonical pathways (Figure 1.6). 
Another drug target within the pathway is the NEMO subunit of the IKK complex. 
Synthetic inhibitors of NEMO have not yet been developed; however, the cell-
permeable NEMO-binding domain (NBD) peptide, derived from the NBD of IKKβ, 
prevents IKK from binding to NEMO and inhibits TNF-induced activation of the 
canonical pathway (Strickland and Ghosh, 2006). In chronic inflammatory diseases like 
rheumatoid arthritis, NF-κB can lead to increased osteoclast differentiation and 
inflammatory bone resorption. Treatment with the NBD peptide inhibits RANKL-
stimulated NF-κB activation and osteoclastogenesis in vitro and in vivo. The peptide 
significantly reduced the severity of collagen-induced arthritis in mice by reducing the 
levels of TNF-α and IL-1β, abrogating joint swelling and reducing destruction of bone 
and cartilage (Jimi et al., 2004). The efficacy of the NBD peptide was tested in 
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inflammatory bowel disease using a colitis mouse model established by adding dextran 
sulfate sodium salt (DSS) to the drinking water and a mouse model established by a 
trinitrobenzene sulfonic acid (TNBS) enema. The peptide was able to reduce colonic 
inflammatory injury in both models by downregulating proinflammatory cytokines 
mediated by NF-κB (Shibata et al., 2007). Activated B-Cell (ABC) Diffuse Large B-Cell 
Lymphoma (DLBCL) is characterized by constitutive canonical NF-κB signaling. In a 
phase I trial, dogs with spontaneous newly diagnosed or relapsed ABC-like DLBCL 
were treated with NBD peptide and biopsies of malignant lymph nodes were taken 
before and 24 hours after treatment. Intravenous delivery of less than 2 mg/kg of NBD 
peptide inhibited constitutive canonical NF-κB activity in 6/10 dogs and showed no 
significant hematological, biochemical, or long-term toxicities. The results suggest that 
systemic administration of NBD peptide is safe, effective, reduces malignant B cell 
proliferation in some dogs and could be relevant for human ABC-DLBCL (Habineza 
Ndikuyeze et al., 2014). Plevy and colleagues showed that NBD peptide reduced colitis 
in an IL-10-deficient murine model of inflammatory bowel disease (Davé et al., 2007). 
Guttridge and colleagues used NBD-treatment to demonstrate the importance of IKK 
and NF-κB signaling in muscle degeneration in the murine model of Duchenne muscular 
dystrophy (Acharyya et al., 2007). Furthermore, NBD peptide improved disease markers 
in the golden retriever model of Duchenne muscular dystrophy (Kornegay et al., 2014). 
Peptides corresponding to the region of NEMO responsible for oligomerization can also 
inhibit NF-κB activity (Agou et al., 2004). 
The IKK-related kinases, IKKε and TBK1 can drive context-specific NF-κB 
signaling and induce NF-κB-independent anti-viral inflammatory responses (Hiscott et 
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al., 2006). Amlexanox (Aphthasol), a small-molecule compound used in the clinic to 
treat aphthous ulcers and asthma, is an inhibitor of these kinases. Remarkably, 
treatment of obese mice with amlexanox elevates energy expenditure through 
increased thermogenesis, producing weight loss, improved insulin sensitivity, and 
decreased hepatic steatosis (Reilly et al., 2013). Experiments performed in double-
knockout MEFs supported these findings. Together, these results and its approved 
status make amlexanox a potential therapeutic for obesity and related disorders. 
IKKε and TBK1 may also promote cell proliferation and cell survival in cancer 
(Barbie et al., 2009; Boehm et al., 2007; Clément et al., 2008; Eddy et al., 2005; Li et 
al., 2014; Muvaffak et al., 2014). Some studies have shown that the IKK-related kinases 
promote KRAS-driven tumorigenesis. TBK1/IKKε promote tumor survival by activating 
CCL5 and IL-6. CYT387, a potent JAK/TBK1/IKKε inhibitor, uniquely disrupts a RAS-
associated cytokine circuit involving CCL5, IL-6, and STAT3, and impairs Kras-driven 
murine lung cancer growth. Treatment in combination with MAPK pathway inhibition led 
to the regression of aggressive Kras mutant and p53 null lung adenocarcinomas in 
mice. The efficacy of CYT387-based treatment in murine Kras-driven lung cancer 
suggests that concurrent inhibition of TBK1/IKKε, Janus-activated kinase (JAK), and 
MEK signaling could be an effective treatment in oncogenic KRAS-driven lung 
adenocarcinoma (Zhu et al., 2014). Although some compounds have displayed 
selective TBK1 inhibition in vitro and in vivo, the development of more efficient and 
selective TBK1 inhibitors is still required (Hasan et al., 2015; Yu et al., 2015). 
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1.4.6.4. IκB Stabilization 
While there are multiple IκB proteins (Figure 1.5), IκBα is the major NF-κB 
inhibitor protein in most cells. Some studies indicate that induced upregulation of IκBα 
expression can be therapeutic in some settings. The natural peptides deposited in brain 
plaques of Alzheimers’ disease patients, called β-amyloid peptides, induce IκBα 
expression. Treatment of rat cortical cultures with these peptides increases IκBα 
expression and decreases activation of NF-κB (Bales et al., 1998). Other studies show 
that anti-inflammatory cytokines like IL-10, IL-11, and IL-13 increase IκBα mRNA levels 
and limit NF-κB nuclear localization (Ehrlich et al., 1998; Lentsch et al., 1997; Trepicchio 
and Dorner, 1998). 
Activated IKKs can rapidly phosphorylate IκBα, leading to its ubiquitination and 
proteasomal degradation. The ubiquitin proteasome system plays an important 
regulatory role in the NF-κB pathway (Chen, 2005). To limit proteasome-mediated 
degradation of IκBα and prevent NF-κB activation, several strategies may be employed. 
Microinjection of phosphopeptides corresponding to Ser32/36 of IκBα can inhibit IκBα 
ubiquitination (Yaron et al., 1997). The SCF-βTrCP E3 ubiquitin ligase complex, which 
leads to rapid degradation of IκBα, can be inhibited with RNAi against βTrCP or by 
overexpressing a dominant-negative βTrCP mutant (Tang et al., 2005). The YopJ 
protein, from the Yersinia bacteria, can deubiquitinate IκBα and prevent NF-κB nuclear 
translocation (Zhou et al., 2005). Although the mechanism is unknown, the small 
molecule Ro 106-9920 can also prevent IκBα ubiquitination and inhibit inflammation 
(Swinney et al., 2002). 
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Several proteasome inhibitors are able to suppress NF-κB activity. MG101, 
MG115, and MG132 are peptide aldehydes capable of inhibiting the chymotrypsin-like 
activity of the proteasome complex (Grisham et al., 1999; Jobin et al., 1998; Palombella 
et al., 1994). Lactacystin and its precursor β-lactone are microbial products that block 
proteasome activity by acylating an active site threonine residue in the β subunits of the 
20S proteasome (Fenteany and Schreiber, 1998; Hayes et al., 2006). PS-262, PS-273, 
PS-341, and PS-402 are peptide boronic acids (or dipeptidyl boronates) that also block 
the chymotrypsin-like activity in the 20S proteasome (Adams, 2004). PS-341, commonly 
known as bortezomib, is the first drug to be approved for clinical application that targets 
the ubiquitin proteasome system (Orlowski et al., 2002). Bortezomib has significant 
efficacy against multiple myeloma (MM), as well as several other hematologic and solid 
tumors (Jagannath et al., 2010), and works in part by stabilizing IκBα and preventing the 
activation of NF-κB (Hideshima et al., 2001; Richardson et al., 2003). However, the 
therapeutic window of bortezomib is relatively narrow due to its side effects (Nowis et 
al., 2010) and the high incidence of intrinsic and acquired resistance (Lü and Wang, 
2013). Therefore, inhibitors of the ubiquitin proteasome system acting through 
mechanisms distinct from bortezomib could serve as effective therapeutic alternatives 
(Eldridge and O'Brien, 2010; Ruschak et al., 2011). 
E1 inhibitors, such as PYR-41, target the ubiquitin-activating enzyme (UBE1) at 
the first step in the ubiquitination cascade (da Silva et al., 2013). PYR-41 has been 
reported to kill tumor cells by inhibiting NF-κB activation, and promoting p53 
accumulation (Yang et al., 2007). NSC697923, an E2 inhibitor of the UBC13-UEV1A E2 
enzyme, blocks the formation of the E2-ubiquitin thioester conjugate (Landré et al., 
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2014). Since UBC13-UEV1A catalyzes the formation of K63-linked polyubiquitin chains, 
this compound inhibits NF-κB activation, and leads to reduced proliferation and viability 
of some cancer cells (Pulvino et al., 2012). E3 ubiquitin ligases represent promising 
targets for therapeutic intervention as key regulators of protein degradation, activation, 
and localization (Berndsen and Wolberger, 2014; Landré et al., 2014). One example is 
the family of E3 ligases composed of Inhibitor of Apoptosis (IAP) proteins such as 
cIAP1/2. These IAPs are interesting targets as they promote anti-apoptotic NF-κB 
activity while inhibiting pro-apoptotic caspases and SMAC proteins (Fulda and Vucic, 
2012). However, it will be hard to predict the specificity of drugs targeting E3 ligases, 
since they will affect the ubiquitination of several different proteins. 
 
1.4.6.5. Blocking Nuclear Translocation 
IκB degradation frees the NF-κB transcription factor to move into the nucleus via 
a subset of importin-α subunits (Fagerlund et al., 2008). Peptides corresponding to the 
nuclear localization sequence of the p50 subunit have been used as a decoy to saturate 
the nuclear import machinery required by NF-κB dimers containing the p50 subunit 
(Letoha et al., 2005; Lin et al., 1995). However, some of these peptides, like SN50, can 
be non-specific and can also block the nuclear localization of other factors including AP-
1, STAT, and NFAT (Boothby, 2001; Torgerson et al., 1998). 
A small molecule, called PBS-1086, has been reported as a dual inhibitor of both 
canonical and noncanonical NF-κB pathways that inhibits NF-κB translocation into the 
nucleus (Fabre et al., 2012; Oh et al., 2011). Dehydroxymethylepoxyquinomicin 
(DHMEQ) is a fungal compound with anti-inflammatory and anticancer effects that 
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inhibits nuclear translocation of RelA/p65 and c-Rel, but not p50 (Umezawa and 
Chaicharoenpong, 2002). DHMEQ, a thiol-reactive compound, targets the conserved 
Cys38 residue of RelA/p65, conferring its specificity (Watanabe et al., 2008). 
 
1.4.6.6. Transcription Factor Inhibition 
In the final phase of NF-κB activation, the transcription factor binds to a stimulus-
dependent suite of target genes. Transcription factors have not traditionally been 
considered optimal drug targets, but their ability to bind DNA and activate transcription 
can be inhibited. Estrogen and glucocorticoid receptors inhibit NF-κB-dependent 
transcription through several mechanisms, including cofactor competition and repressor 
protein recruitment (De Bosscher et al., 2006; Garside et al., 2004; Kalaitzidis and 
Gilmore, 2005; Ling and Kumar, 2012). Several of the thiol-reactive compounds used to 
target Cys179 of IKKβ can also prevent DNA-binding by interacting with a conserved 
cysteine residue in the DNA-binding loop of the NF-κB/Rel subunits (Pande et al., 
2009). Using this mechanism, some natural products and their derivatives like 
epoxyquinone A monomer (EqM) and parthenolide can target two stages of the pathway 
and inhibit both IKKβ activation and transcription factor binding (García-Piñeres et al., 
2004; Kwok et al., 2001; Liang et al., 2006; Straus et al., 2000). However, these 
compounds may lack specificity and are likely to interact with the reactive cysteine 
residues in many different proteins. 
Dimethyl fumarate (DMF) is an anti-inflammatory drug in clinical use for multiple 
sclerosis that also inhibits the NF-κB pathway (Cross et al., 2011; Gillard et al., 2015; 
Nicolay et al., 2016; Seidel et al., 2009). In breast cancer cells, Kastrati and colleagues 
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showed that DMF effectively abrogates NF-κB-dependent mammosphere formation, 
inhibits cell proliferation, and significantly impairs xenograft tumor growth. In addition, 
their data suggest that DMF blocks NF-κB activity by covalently modifying RelA/p65 at 
Cys38, which prevents RelA/p65 nuclear translocation and attenuates its DNA binding 
activity (Kastrati et al., 2016). 
Decoy oligonucleotides corresponding to the NF-κB DNA binding site and oligo-
peptide analogs can compete for binding of activated NF-κB dimers (Edwards et al., 
2009). Some of these decoy oligonucleotides have had positive results in animal 
models (Desmet et al., 2004; Matsuda et al., 2004) and have gone on to clinical trials. 
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Figure 1.7. Inhibition of the NF-κB pathway. The majority of research into developing inhibitors of the 
canonical pathway has been focused on selectively targeting IKK. However, there are a number of other 
possible therapeutic approaches. NF-κB decoy oligos and RNAi can target binding to DNA and regulation 
of NF-κB protein expression; NBD peptide can interfere with the formation of the IKK complex; the TIRAP 
inhibitor peptide, antioxidants, and Hsp90 inhibitors can block IKK activation (Hsp90 stabilizes RIP protein 
components of the TNF-α receptor signaling complex); proteasome inhibitors can stabilize IκB; IκBα 
super-repressor can inhibit NF-κB nuclear translocation; and glucocorticoids can inhibit NF-κB 
transcriptional activity. Due to the complex and variable mechanisms in regulating NF-κB signaling, more 
research is needed to develop new, more effective and clinically useful inhibitors. TIRAP, Toll-interleukin-
1 Receptor domain-containing Adapter Protein. Modified from (Gilmore and Garbati, 2011; Karin et al., 
2004). 
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1.4.7. IKK/NF-κB and Anticancer Drug Resistance 
Radiation and conventional chemotherapies activate NF-κB and lead to 
increased expression of target genes that promote proliferation and survival (e.g. 
cIAP1/2, Bcl-2, and Bcl-xL). In this setting, the cancer cells will acquire NF-κB-
dependent resistance to anticancer treatment (Chuang et al., 2002; Kesanakurti et al., 
2013; Wang et al., 1996; 1999). The NF-κB inhibitor DHMEQ is able to re-sensitize 
prostate cancer cells to chemotherapy by decreasing the expression of Snail and Bcl-xL 
and increasing the levels of RKIP, a negative regulator of NF-κB (Baritaki et al., 2009). 
In BRCA mutant cancers cells, PARP inhibitors have shown anticancer activity. 
However, these tumors eventually develop drug resistance with a preferential 
upregulation of the NF-κB pathway, suggesting an NF-κB-dependent mechanism for 
acquired resistance. The PARP inhibitor-resistant cells are also sensitive to the 
inhibitors of NF-κB, Bay 11-7082 or bortezomib (Nakagawa et al., 2015). 
In mouse models of KRAS-driven lung adenocarcinoma, studies have identified 
NF-κB as a promising therapeutic target important for tumor initiation and maintenance 
(Bassères et al., 2010; Meylan et al., 2009). Synthetic small-molecule NF-κB inhibitors 
bortezomib (Velcade/PS-341) and Bay-117082 induces tumor regression and prolongs 
survival in tumor-bearing KrasLSL-G12D/wt; p53flox/flox mice. However, sustained bortezomib 
or Bay 11-7082 treatment inevitably confers drug resistance to the tumors (Xue et al., 
2011). Since some cancer cells can achieve resistance to chemotherapy and radiation 
through activation of NF-κB, inhibiting the pathway in the right context and in 
combination with conventional therapies could significantly improve the efficacy of 
cancer treatment (Nakanishi and Toi, 2005). 
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1.4.8. Clinical Trials 
While drugs such as aspirin exhibit clinical benefits related to blocking NF-κB 
activity (Yin et al., 1998), trials testing the specific inhibition of NF-κB remain scarce. A 
comprehensive database of clinical studies curated by the US National Institutes of 
Health can be found at the ClinicalTrials.gov website. One clinical trial testing the anti-
inflammatory effects of indirect IKK/NF-κB inhibition uses Denosumab, a monoclonal 
antibody against receptor activator of NF-κB ligand (RANKL) in Crohn's disease. This 
study’s sponsor (Identifier: NCT02321280), University of Manitoba, is conducting phase 
I and phase II trials. In another phase II trial (Identifier: NCT02280785), sponsored by 
the Samsung Medical Center, researchers are testing the anticancer effects of indirect 
IKK/NF-κB inhibition using Brentuximab vedotin (Adcetris), an antibody-drug conjugate 
targeting CD30, one of surface antigens expressed in lymphoma cells. CD30 
(TNFRSF8) is a transmembrane glycoprotein of the TNF receptor superfamily involved 
in the activation of the NF-κB pathway and the mitogen-activated protein kinases 
(MAPKs), ultimately modulating cell growth, proliferation and apoptosis. In January 
2016, AnGes MG, a Japanese biotechnology company, announced the completion of 
patient enrollment for the phase III clinical trial of its NF-κB decoy oligonucleotide drug 
for atopic dermatitis. 
 
1.4.9. Summary 
As a crucial regulator of inflammation and cell survival, the importance of the NF-
κB pathway in disease is clear. The challenge lies in how to optimize therapeutic 
strategies for target specificity, disease context, dosage, toxicity, schedules, adjuvants, 
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drug combinations, side effects, and resistance. Some strategies have been more 
effective than others. Anti-TNF drugs continue to provide significant clinical benefit, but 
these are accompanied by side effects including lymphomas, infection, autoimmunity, 
and heart failure. The NBD peptide has shown promise in animal trials, but whether it 
can be used safely and effectively in humans remains to be seen. Then, there are the 
IKK inhibitors, which have served researchers for years as reliable tool compounds, but 
have not been able to move beyond animal studies and into the clinic. Even with 
numerous IKK inhibitor compounds, very few can reliably distinguish between IKKα and 
IKKβ, and none are able to selectively target IKKα (Tian et al., 2015). 
Ideally an IKK/NF-κB inhibitor should be highly specific and prevent activation 
without affecting other signaling pathways, at least not directly. This ideal inhibitor 
should be more active in diseased cells than in normal cells or it should be amenable to 
targeted delivery (drug-loaded nanoparticles) (Zhang et al., 2016). It should be efficient, 
but transient and reversible since long-term immunosuppression would be unfavorable, 
considering the important role of NF-κB in the innate immune system. Finally, the 
efficacy of this ideal inhibitor as a single agent and in combination with other therapeutic 
agents would have to be thoroughly understood. 
Elucidating the specific sequence of events that shapes the context-dependent 
NF-κB response is an important first step in designing a clinically relevant and truly 
specific strategy for NF-κB inhibition in disease. In addition to immunosuppression, a 
major caveat associated with long term IKK/NF-κB inhibition would be increased 
susceptibility to endotoxin-induced shock. Studies have shown that sustained inhibition 
of IKKβ in mice results in enhanced production of IL-1β and related cytokines and 
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increases susceptibility to endotoxin-induced shock due to upregulated inflammasome 
activation during bacterial infections (Greten et al., 2007). If this scenario were 
unavoidable, inhibitors would have to be limited to short durations and paired with 
antibiotics (Baud and Karin, 2009). 
In September 2016, the Cancer Moonshot Blue Ribbon Panel led by the United 
States presented a report describing plans for making a decade’s worth of progress in 
cancer research by the year 2020. Called the Cancer Moonshot 2020, it is the most 
comprehensive collaborative initiatives ever assembled for cancer research. The 
initiative hopes to accelerate the implementation of immunotherapy as the new standard 
of care for cancer patients - transitioning from therapies that decimate the immune 
system (radiation, chemotherapy) to an approach that would empower the immune 
system. This would potentially allow patients to manage cancer in a manner similar to 
diseases such as diabetes, asthma, or other chronic diseases. The IKK/NF-κB pathway 
is essential to immune response, but the pathway is also a major culprit in cancer. It will 
be important to determine if progress can be made towards successfully blocking IKK or 
NF-κB in cancer without impairing the immune system, and whether there is still a place 
for these strategies in a future where immunotherapy is the standard of care. 
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CHAPTER II: GENOME-WIDE DNA METHYLATION ANALYSIS OF 
KRAS MUTANT CELL LINES1 
2.1. OVERVIEW 
Oncogenic Ras mutations are associated with DNA methylation changes that 
alter gene expression relevant to the cancer phenotype. Recent studies suggest these 
DNA methylation changes may be stochastic in nature, while other groups propose 
elaborate pathways responsible for aberrant methylation. Ultimately, a better 
understanding of the DNA methylation events associated with oncogenic KRAS 
expression could enhance therapeutic approaches. Here we analyze the basal CpG 
methylation of 11 KRAS dependent pancreatic cancer cell lines and observe strikingly 
similar basal methylation patterns. However, KRAS knockdown results in unique 
methylation changes with limited overlap between each cell line. In Pa16C pancreatic 
cells, while KRAS knockdown results in over 8000 differentially methylated (DM) CpGs, 
treatment with the ERK inhibitor SCH772984 shows less than 40 DM CpGs, suggesting 
that ERK is not a broadly active driver of KRAS-associated DNA methylation. KRAS 
G12V overexpression in an isogenic lung model reveals >50,600 DM CpGs compared 
to non-transformed controls. In lung and pancreatic cells, gene ontology analyses of the 
cell line specific DM promoters show enrichment for genes involved in differentiation 
                                                        
1 The work described in this chapter will be submitted as part of a manuscript for the journal, Scientific 
Reports. The following authors contributed to this study: Joel K. Durand, Kirsten L. Bryant, Ben Yi Tew, 
Tikvah K. Hayes, Sen Peng, Nhan L. Tran, Gerald C. Gooden, Channing J. Der, Albert S. Baldwin and 
Bodour Salhia. 
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and development. These epigenetically altered genes associated with KRAS expression 
could represent potential therapeutic targets in KRAS-driven cancer. 
 
2.2. INTRODUCTION 
Activating KRAS mutations can be found in nearly 20 percent of all cancers 
(Hobbs et al., 2016). Pancreatic and lung cancers, in particular, exhibit high rates of 
oncogenic KRAS mutation, at 90% and 30%, respectively (Simanshu et al., 2017). In 
addition to the high frequency of mutations, KRAS has been established as a crucial 
oncoprotein in the progression and maintenance of KRAS mutant pancreatic and lung 
cancers (Eser et al., 2014; Ji et al., 2007; Kim et al., 2016; Massarelli et al., 2007; Riely 
et al., 2009; Zeitouni et al., 2016). The important role of oncogenic KRAS in cancer has 
been met with a decades-long effort to inhibit aberrant KRAS signaling (Janes et al., 
2018; Ostrem et al., 2013). However, nearly all attempts to directly target oncogenic 
KRAS have been unsuccessful. Instead, the inhibition of downstream effectors has 
served as a practical alternative thus far. Small compounds targeting KRAS effectors 
like the RAF-MEK-ERK MAPK cascade and the PI3K-AKT-mTOR pathway have yielded 
varying results (Eser et al., 2013; Hayes et al., 2016; Riquelme et al., 2016; Wee et al., 
2009; Wong et al., 2010). Recent studies suggest that drug resistance and relapse will 
continue to be a major hurdle in the clinic, even in a world where KRAS inhibition is 
possible (Muzumdar et al., 2017; Singh et al., 2009; Sunaga et al., 2011). 
In addition to aberrant effector signaling, KRAS mutant cancer cells also undergo 
genome-scale epigenetic changes including DNA methylation. In genomic DNA, 
cytosine residues in CpG sequences are methylated at the fifth position (5-
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methylcytosine, 5mC) by DNA methyltransferases (DNMTs) (Deaton and Bird, 2011). 
DNMT1, maintains the methylation state during cell division, and shows a preference for 
hemi-methylated DNA. Whereas, DNMT3a and DNMT3b function as de novo 
methyltranferases and are responsible for generating brand new methylation patterns 
(Klose and Bird, 2006). CpG methylation can have effects on chromatin structure and 
regulate gene expression (Baylin, 2005). The mechanism by which CpG methylation 
represses gene expression is not fully understood; however, studies suggest that 
methylated CpGs block transcription factor binding at promoter regions, recruit 
heterochromatin factors, or recruit histone deacetylases (HDACs) via methyl-CpG-
binding domain proteins (Baylin, 2005). CpG methylation plays an important role in 
normal development and is more stably maintained than chromatin modifications. Gene 
imprinting, X chromosome inactivation, transposons, all which require long-term 
silencing, utilize this epigenetic mechanism (Horii and Hatada, 2016). However, CpG 
methylation is reversible, and can be dynamically regulated. The Tet hydroxylase 
proteins are able to catalyze the hydroxylation of 5mC to 5-hydroxymethylcytosine 
(5hmC), subsequently leading to the formation of 5-formylcytosine (5fC) and 5-
carboxylcytosine, which are both ultimately removed by thymine DNA glycosylase and 
base excision repair (He et al., 2011). 
Global DNA hypomethylation and focal hypermethylation at CpG islands have 
become hallmarks of cancer (Belinsky, 2004; Jones and Baylin, 2002; Sharma et al., 
2010). Moreover, oncogenic KRAS expression has specifically been shown to induce 
aberrant DNA methylation, promoting hypomethylation across the genome while 
silencing key tumor suppressors through hypermethylation (Gazin et al., 2007; Serra et 
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al., 2014). This KRAS-associated differential DNA methylation could have a significant 
impact on promoter regulation across the genome and lead to important oncogenic 
transcriptional changes. Discovering an essential and predictable epigenetic response 
to mutant KRAS expression would reveal other potential anti-cancer targets. However, 
in a recent study using fibroblasts, Xie et al. found that HRAS-transformed cells show 
methylation patterns diverging dramatically compared with the reproducible methylation 
pattern of senescence (Xie et al., 2018). The authors suggest that transformation 
involves stochastic epigenetic patterns from which malignant cells may evolve. 
Ultimately, a better understanding of the DNA methylation events associated with 
oncogenic KRAS expression could enhance therapeutic approaches for KRAS-driven 
cancers and provide a platform for understanding the intrinsic heterogeneous nature of 
these cancers. 
Here we perform a genome-scale analysis using KRAS mutant human pancreatic 
cancer cell lines to investigate whether suppression of mutant KRAS correlates with 
differential DNA methylation at genomic loci and the role of ERK in this process. We 
also investigate whether mutant KRAS overexpression is associated with differentially 
methylated genes and the biological processes involved. 
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2.3. RESULTS 
2.3.1. Clustering of pancreatic cancer cells shows similar basal CpG methylation 
patterns independent of KRAS mutation status 
Studies examining the cancer methylome have revealed aberrant DNA 
methylation patterns across several cancer types (De Carvalho et al., 2012). Given the 
essential role of oncogenic KRAS in pancreatic cancer (Hayes et al., 2016; Bryant et al., 
In Review) (Figure 2.1), we investigated whether the presence of oncogenic KRAS 
mutation correlates with specific patterns in global DNA methylation. We first performed 
genome-wide DNA methylation profiling of 11 KRAS dependent pancreatic cancer cell 
lines using the Infinium HumanMethylation450 BeadChip Array (Bibikova et al., 2009). 
We compared our panel of KRAS mutant pancreatic cancer cells transduced with non-
silencing (NS) shRNA to published Infinium methylation data from ENCODE (ENCODE 
Project Consortium, 2012; Sloan et al., 2016) (Figure 2.2). These published ENCODE 
data include 4 non-tumorigenic cell lines and 30 cancer cell lines of varying cell type 
and genetic background. Unsupervised hierachial clustering of the top 1000 most 
variable CpG probes across all 47 cell lines did not reveal clustering based on KRAS 
mutation status. In general, the cell lines formed clusters based on cell type with a few 
exceptions, suggesting that even as KRAS may influence some key changes to the 
epigenome, the bulk of the DNA methylation patterns observed may be cell type specific 
and a consequence of cell state and cell lineage. Nonetheless, with the exception of 
CFPAC-1 and PANC-1 cells, the panel of KRAS mutant pancreatic cancer cell lines 
clustered together (Figure 2.2). These data suggest that the panel of KRAS mutant 
pancreatic cancer cell lines contain similar DNA methylation patterns. 
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Figure 2.1. RNAi screens against KRAS showing pancreatic cell line dependence on KRAS 
expression. A. Comparison between two RNAi datasets including 5 of the cell lines used in our 
methylation study; Achilles (Demeter) was performed by the Broad Institute and DRIVE (ATARiS) was 
performed by Novartis. The more negative, the more the cell line is dependent on KRAS expression. B. A 
CRISPR (Avana CRISPR Library) screen performed by the Broad Institute. The more negative, the more 
the cell line is dependent on KRAS. Generated using the Broad Institute Dependency Map 
(https://depmap.org/portal/). 
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Figure 2.2. Clustering of pancreatic cancer cells shows similar basal CpG methylation patterns 
independent of KRAS mutation status. DNA methylation analysis was perfomed using ~450,000 
Infinium CpG probes in 11 human pancreatic cancer cell lines transduced with non-silencing (NS) shRNA: 
Pa16C_NS, Pa01C_NS, PANC-1_NS, Panc 10.05_NS, Pa04C_NS, Pa02C_NS, CFPAC-1_NS, 
HPAC_NS, HPAF-II_NS, SW-1990_NS and Pa18C_NS cells. DNA methylation patterns in these 
pancreatic cells were compared to the DNA methylation in lung epithelial SALEB and SAKRAS cells 
(described in the text) and Infinium methylation data obtained from ENCODE (www.encodeproject.org). 
Unsupervised hierarchical Manhattan-Ward clustering analysis using the top 1000 most variable CpG 
probes across all 47 cell lines is displayed above. The pancreatic cell lines transduced with NS shRNA 
clustered together, with the exception of CFPAC-1_NS and PANC-1_NS cells. However, there was no 
clustering based on KRAS mutation status. Each row represents a probe and each column represents a 
sample. The β value (level of DNA methylation) for each probe is represented with a color scale as shown 
in the key. Values closer to 1 represent hypermethylation, while values closer to zero represent 
hypomethylation. 
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2.3.2. Unsupervised hierachical clustering shows cell line specific differential 
CpG methylation associated with KRAS suppression in pancreatic cancer cells 
While DNA methylation patterns appear to be most influenced by cell state and 
tissue of origin, we hypothesized that silencing KRAS in the KRAS dependent 
pancreatic cancer cells would still lead to differential DNA methylation at loci that require 
KRAS activity to maintain their methylation status. Also, considering the similarity 
among the basal CpG methylation patterns of the pancreatic cells (Figure 2.2), we 
hypothesized that the changes in response to KRAS suppression would be relatively 
similar. To test these hypotheses, cells were harvested for RNA and genomic DNA 4 to 
7 days after shRNA transduction. Reduced KRAS mRNA levels were observed in 
KRAS-depleted cells relative to NS controls as determined by RNA sequencing (Figure 
2.3A). Unfortunately, RNA was not collected for SW-1990 cells due to insufficient 
material. Unsupervised hierarchical clustering using the top 1000 most variable CpG 
probes revealed cell line clusters in which all 11 KRAS-depleted cell lines and their 
isogenic controls appear more similar to each other than any other cell line (Figure 
2.3B). Surprisingly, there were no differentially methylated (DM) CpGs associated with 
KRAS knockdown that overlapped between more than 4 of the pancreatic cancer cell 
lines. An ANOVA analysis was performed in which cell lines Pa16C, Pa01C, and Panc 
10.05 clustered together, while all other cell lines assembled into KRAS/NS cell line 
pairs (Figure 2.4A). Heirachical clustering using a total of 204 CpG probes with Δβ 
values ≥0.2 or ≤-0.2 in three or more cell line pairs also showed cell lines Pa16C, 
Pa01C, and Panc 10.05 clustering together (Figure 2.4B). A number of the genes 
corresponding to the top 10 differentially methylated CpGs with Δβ values ≥0.2 or ≤-0.2 
 57 
in at least 3 out of 11 cell line pairs are reported to have biologically essential functions 
(Figure 2.4C). However, due to the limited number of DM CpGs that overlapped 
between cell lines, we focused our analysis on the KRAS dependent DNA methylation 
changes unique to each cell line pair instead of the changes of the panel as a whole. 
The DNA methylation profiles of Pa16C, Pa01C, PANC-1, and Panc 10.05 cells showed 
the most robust response to KRAS suppression. These four cell lines were the most 
responsive to KRAS suppression and showed at least 5-fold more DM CpGs compared 
to the seven other pancreatic cell lines tested (Figure 2.3D and Table 2.1). In addition, 
although Pa16C cells are apparently derived from Panc 10.05 cells (Jones et al., 2008), 
Pa16C cells had more than 4 fold the number of DM CpGs (Figure 2.3D and Table 
2.1). The four responsive cell lines showed a significant number of DM CpGs located in 
the promoter region (200-1500 nt upstream of the transcription start site) of dozens of 
functionally important genes (Table 2.2). Though not formally tested, we postulate that 
these cell line specific responses to KRAS suppression may also be influenced by cell 
state and genetic background. Taken together these results suggest that oncogenic 
KRAS expression is associated with differential DNA methylation; however, whether a 
cell’s CpG methylation profile is sensitive or refractory to KRAS suppression likely 
depends on the cell state and genetic background. 
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Figure 2.3. Unsupervised hierachical clustering shows cell line specific differential CpG 
methylation associated with KRAS suppression in pancreatic cancer cells. A. KRAS mRNA levels 
from 10 pancreatic cancer cell lines transduced with KRAS shRNA compared to non-silencing (NS) 
controls as measured by RNA sequencing. RNA was not collected for SW-1990 cells due to insufficient 
material. B. Unsupervised hierarchical Manhattan-Ward clustering analysis was performed using the top 
1000 most variable CpG probes across the panel of 11 pancreatic cell lines transduced with NS shRNA 
or KRAS shRNA. These samples assemble into cell line pairs and show cell specific differential DNA 
methylation with KRAS knockdown. The β value (level of DNA methylation) for each probe is represented 
with a color scale as shown in the key. C. Box plot showing the distribution of Δβ values (level of 
differential DNA methylation) in each cell line pair (KRAS shRNA cells compared to NS shRNA controls). 
Negative values indicate hypomethylation, while positive values indicate hypermethylation. D. Bar graph 
showing the number of differentially methylated CpGs with Δβ values ≥0.2 or ≤-0.2 in cell lines 
transduced with KRAS shRNA (hypermethylated CpGs represented in yellow and hypomethylated CpGs 
represented in blue). 
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Figure 2.4. Cell line clustering shows cell-specific differential DNA methylation with KRAS 
knockdown in pancreatic cells. A. ANOVA analysis was performed and a filtered probe list generated 
for each cell line pair. All cell line pairs filtered with (>0.2 or < -0.2) except: PANC-1 (0.4), Pa01C (0.4), 
Panc 10.05 (0.3), Pa16C (0.4). Individual cell line pair filtered lists combined and used for hierarchical 
clustering. Total number of unique probes = 2497. Cell lines Pa01C, Panc 10.05 and Pa16C cluster 
together, with their KRAS knockdown variants most similar to each other. All other cell line pairs show 
their KRAS/NS clustering together. B. Total of 204 probes used for clustering had Δβ values ≥0.2 or ≤-0.2 
in three or more cell line pairs. C. Genes corresponding to top 10 differentially methylated CpGs with Δβ 
values ≥0.2 or ≤-0.2 in at least 3 out of 11 cell line pairs. 
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2.3.3. Comparison between ERK inhibitor treatment and KRAS suppression in 
Pa16C pancreatic cancer cells 
Next, we investigated whether the methylation changes associated with KRAS 
suppression are dependent on ERK, the major downstream effector of KRAS. To test 
this, Pa16C cells, the cell line with the greatest DM CpGs associated with KRAS 
suppression (Figure 2.3D), were treated with the ERK inhibiter, SCH772984 (Figure 
2.5). Cells were harvested for protein and genomic DNA 3 and 7 days after treatment 
with SCH772984. ERK inhibitor treatment led to growth arrest and changes in cell 
morphhology (Figure 2.5A, Right) and also reduced total ERK protein and 
phosphorylated ERK protein as measured by western blot (Figure 2.5A, Left). Modest 
separation between treatment type (DMSO vs SCH) was observed. However, only 1 
significant probe was found in both samples - cg18988094 is hypomethylated in both 3 
day and 7 day ERKi treated samples. This differentially methylated (DM) CpG is found 
near the gene STIP1, which has been reported to activate ERK signaling. (Figure 
2.5B). We then compared DM CpG profiles of the ERK inhibitor treated Pa16C cells to 
the Pa16C cells transduced with shKRAS. Surprisingly, there were no overlapping DNA 
methylation changes between the ERK inhibitor treated (<40 DM CpGs) and the KRAS 
shRNA transduced Pa16C cells (>8000 DM CpGs) despite the similar effects on cell 
growth observed in both conditions (Figure 2.5A, Right) (Hayes et al., 2016). These 
observations suggest that targeted ERK inhibition leads to Pa16C cell growth arrest 
similar to the growth arrest observed in KRAS shRNA transduced Pa16C cells. 
However, ERK does not appear to be an active driver of the thousands of KRAS-
associated DM CpGs present in the KRAS shRNA transduced Pa16C cells (Table 2.1). 
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Figure 2.5. Comparison between ERK inhibitor treatment and KRAS suppression in Pa16C 
pancreatic cancer cells. A. (Left) Western blot showing relative abundance of total and phosphorylated 
ERK in Pa16C cells. Pa16C cells were treated with fresh SCH772984 every 48 hours for 7 days. (Right) 
Phase contrast image of Pa16C cells after 3 and 7 days of treatment every other day with the ERK 
inhibitor SCH772984. B. Significant probes for 3 day and 7 day ERK inhibitor treatment were selected 
based on p-values < 0.05 and Δβ values ≥0.2 or ≤-0.2. The p-values for each probe were calculated using 
DMP tool. Modest separation between treatment type (DMSO vs SCH) was observed. However, only 1 
significant probe was found in both samples - cg18988094 is hypomethylated in both 3 day and 7 day 
ERKi treated samples. This differentially methylated (DM) CpG is found near the gene STIP1, which has 
been reported to activate ERK signaling. No common DM CpGs between ERK inhibitor and KRAS 
shRNA treatment in Pa16C cells were found. 
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Cell Line KRAS CDKN2A TP53 SMAD4 Hypermethylated PromCpGs / CpGs 
Hypomethylated 
PromCpGs / CpGs 
All CpGs with Δβ 
≥ 0.2 or ≤ -0.2 
Pa16C G12D/WT  I255N*  434 / 3275 764 / 5613 8888 
Pa01C G12D/WT  T155P* Del* 175 / 1248 393 / 2998 4246 
PANC-1 G12D/WT Del* R273H*  128 / 717 556 / 3136 3853 
Panc 10.05 G12D/WT  I255N/WT  59 / 452 275 / 1508 1960 
Pa04C G12V* Del* Del*  13 / 172 25 / 200 372 
Pa02C Q61H* Del* L247P* Del* 28 / 185 28 / 184 369 
CFPAC-1 G12V/WT  C242R* Del* 7 / 89 12 / 115 204 
HPAC G12D* Stop/Stop   16 / 104 15 / 92 196 
HPAF-II G12D/WT Del-FS* P151S*  14 / 96 5 / 68 164 
SW-1990 G12D* Del*   11 / 78 15 / 79 157 
Pa18C G12D/WT Del*  Del* 6 / 72 6 / 72 144 
 
Table 2.1. Mutation status of crucial genes and the total number of differentially methylated (DM) CpGs 
with Δβ value ≥0.2 or ≤-0.2 in KRAS-depleted pancreatic cancer cell lines. The CpG methylation in 
Pa16C, Pa01C, PANC-1 and Panc 10.05 cells appears to be the most responsive to KRAS depletion. 
Homozygous mutations are represented by asterisk. PromCpGs, DM CpGs (i) in a promoter region (200-
1500 bases upstream of the transcription start site of a gene) and (ii) within 4 kb of a CpG island 
(including CpGs at shores and shelves). 
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Pa16C cells Pa01C cells PANC-1 cells Panc 10.05 cells 
Hyper- 
methylated 
Hypo- 
methylated 
Hyper- 
methylated 
Hypo- 
methylated 
Hyper- 
methylated 
Hypo- 
methylated 
Hyper- 
methylated 
Hypo- 
methylated 
Transcription Factors 
ASCL2 PFDN5 ARNT HOXD8 SMARCA5 ALX1 ALX4 PAX7 ID3 AIRE LSR ASCL1 BNC2 LHX4 
CBX4 RAX ATOH7 INSM2 TAF3 ALX3 BARHL2 PDX1 KLF14 CUX2 MAF BRF1 C13orf15 LIN28A 
CRIP1 RING1 BACH2 IRF7 THRB EZH1 BHLHE22 PHOX2A MLLT6 EBF4 NEUROG1 MKX CASZ1 LYL1 
E2F2 RREB1 BAZ2B IRX1 TMF1 HMGB2 BNC1 PHOX2B MSX2 EGR3 NFATC4 NEUROG1 CBFA2T3 MSC 
EBF4 SALL4 BRF1 IRX2 TRIM13 HMX2 BRF1 PITX2 NKX2-5 EMX1 NKX2-6 ZFP30 ESR2 MSX1 
ELK3 SIX3 BTF3 LIN28A TRIM27 HOXB1 DBX1 PLAGL1 NKX3-1 ETV7 NKX6-2  EVX2 PAX7 
EOMES TCF7 CECR6 LMX1B TSC22D2 IRX1 DBX2 PRDM13 PAX1 FOXA2 NRIP1  FEZF2 PCGF3 
EYA2 TLX2 CNPY3 MED24 TSHZ3 KDM3B DLX1 RNF2 PRDM8 FOXB1 PBX4  FOXE3 RARG 
FOXC2 TUB CSRP1 MIXL1 TWIST1 LHX8 DMRT1 RORB TBX2 FOXD3 PER1  FOXI1 RUNX3 
FOXE1 TULP1 CSRP2 MKX ULK2 NEUROG1 DMRTA2 RUNX3 TCF7L2 FOXF1 PHF11  GBX2 SALL1 
GBX1 UNCX CUX2 MSX2P1 UTF1 NKX2-2 ESR1 SALL3 YAF2 GATA5 PITX3  GSC SALL3 
GSX1 VENTX ELK4 NCALD VAX1 PAX3 EYA4 TBX3 ZNF213 GFI1 POU3F1  HKR1 T 
HAND1 ZAR1 EN1 NEUROG1 VSX1 SOX8 FEZF2 TCF4 ZNF222 GSC2 RARA  HOXA9 TLX3 
HAND2 ZBTB16 ERMP1 NEUROG3 YBX2 TLX2 FOXB1 ULK2  GSX1 RAX  HOXB13 TUB 
HES2 ZFP28 ESR1 NFYC ZBTB22 TWIST1 GBX2 ZIC1  HAND1 RORB  HOXB2 VEZF1 
HNF1A ZSCAN12 ESRRG OLIG1 ZFP30 ZNF213 GCM2 ZNF16  HAND2 SIM2  HOXB4 ZBTB16 
HOXB1  EYA4 PDLIM5 ZIC1 ZNF593 GFI1 ZNF18  HES4 SIX2  HOXB8 ZBTB17 
HOXC10  FOXE3 PHOX2A ZMYND11  HIC1 ZNF256  HEYL TBX5  IRX2 ZFP28 
HOXC4  FOXG1 PLAGL1 ZNF124  HOXA6 ZNF331  HLX THRB  IRX3 ZIC1 
HOXD12  GBX2 POU3F2 ZNF135  HOXA9   HMX3 TOX  LEF1 ZNF236 
HOXD3  GLI3 POU4F1 ZNF18  HOXB13   HNF1A VENTX    
HOXD4  GRHL1 PPARG ZNF207  HOXB2   HNF1B WT1    
HOXD9  HIF3A PRDM13 ZNF211  HOXC9   HOXC13 YBX2    
IRF4  HMX3 PRDM14 ZNF219  HOXD3   HOXD1 ZAR1    
KCNIP3  HOXA5 PRDM6 ZNF232  ID4   HR ZFP37    
MYCNOS  HOXA9 RARG ZNF268  IRF7   IRF6 ZNF229    
NEUROG2  HOXB13 RBBP9 ZNF295  MKX   IRF8 ZNF334    
NFIC  HOXB3 RUNX3 ZNF318  MSC   ISL1 ZNF701    
NKX6-1  HOXB4 SALL1 ZNF532  MSX1   LEF1 ZSCAN12    
NKX6-3  HOXB8 SALL3 ZNF682  NKX2-5        
OSR1  HOXC8 SAMD4B   NKX6-2        
OTP  HOXD1 SIM2   PAX1        
              
Cytokines & Growth Factors 
BDNF LEFTY1 BMP3 FGF2 NRG3 FGF20 CALCA GRP CXCL5 BMP2 LTBP2 CALCA CMTM2 SCT 
CALCA LTBP3 CCK FGF20 PTHLH GDF6 CMTM2 HAMP KL BMP7 MDK CCK FGF2 SEMA5A 
CSF1 PDGFRA CMTM1 FGF5 SEMA6D IL28B EPO NGF  BMP8A NGF  GRP SLIT1 
CXCL12 PENK CMTM3 FGF9 SLIT1 NRG3 FGF11 PSPN  CXCL16 NRG1  NPY  
FGF19 PTH2 DKK1 GDNF TNFSF13 PDGFA FGF12 SEMA5A  EDN3 NRG3    
GDF7 SCGB3A1 EPO GREM1  SEMA6B FGF2 SLIT1  FAM3B RLN3    
KL SECTM1 FGF11 KITLG   GREM1 SLIT2  FGF22 STC2    
         FGF6 TNFSF12    
         GDF10 TYMP    
         GDF7 VEGFC    
         GRP     
              
Homeodomain Proteins 
GBX1 NKX6-1 CUX2 HOXC8 POU3F2 ALX1 ALX4 HOXD3 MSX2 CUX2 ISL1 MKX EVX2 HOXB8 
GSX1 NKX6-3 EN1 HOXD1 POU4F1 ALX3 BARHL2 MKX NKX2-5 EMX1 NKX2-6  GBX2 IRX2 
HNF1A OTP GBX2 HOXD8 TSHZ3 HMX2 DBX1 MSX1 NKX3-1 GSC2 NKX6-2  GSC IRX3 
HOXB1 RAX HMX3 IRX1 VAX1 HOXB1 DBX2 NKX2-5  GSX1 PBX4  HOXA9 LHX4 
HOXC10 SIX3 HOXA5 IRX2 VSX1 IRX1 DLX1 NKX6-2  HLX PITX3  HOXB13 MSX1 
HOXC4 TLX2 HOXA9 LMX1B  LHX8 GBX2 PAX7  HMX3 POU3F1  HOXB2 PAX7 
HOXD12 UNCX HOXB13 MIXL1  NKX2-2 HOXA6 PDX1  HNF1A RAX  HOXB4 TLX3 
HOXD3 VENTX HOXB3 MKX  PAX3 HOXA9 PHOX2A  HNF1B SIX2    
HOXD4  HOXB4 MSX2P1  TLX2 HOXB13 PHOX2B  HOXC13 VENTX    
HOXD9  HOXB8 PHOX2A   HOXB2 PITX2  HOXD1     
      HOXC9        
              
Protein Kinases 
CAMK2B PDGFRA AATK MAPK7 PINK1 CDK6 CDKL3  BRAF ACVR1C KDR PRKAA2 CDC42BPB NEK3 
FASTK STK19 BRAF MYO3A SGK1 DDR1 DCLK2  CSNK1A1 BCR KSR2 RIPK3 FGFR1 NTRK3 
HUNK TNK2 CDC42BPB NEK10 SNRK EIF2AK2 NEK9   CDKL2 MAST4    
KDR  CDKL3 NEK3 STYK1 HIPK3 PDK2   CSNK1G2 MST1R    
LCK  FGFR1 NRBP1 ULK2 MAP2K1 PINK1   DAPK1 PBK    
MAP3K6  FGR NTRK3  MAPK4 RIOK3   DMPK STK32A    
MAPK12  FYN PBK  MATK ULK2   EPHA6 STK32B    
     PRKD1    FGFR1 STK33    
     RYK    FLT3 SYK    
         HCK TNK1    
         HUNK WNK2    
         INSR     
              
Oncogenes 
CCND2 ZBTB16 ARNT GAS7 PPARG CCND2 HOXA9  BRAF BCR KDR  CBFA2T3 NTRK3 
IRF4  BRAF GNAS TOP1 CDK6 PAX7  CCND1 CDH11 MAF  FGFR1 PAX7 
KDR  ELK4 HOXA9 TRIM27 JAK2 ZNF331  MLLT6 DDX6 PER1  HOXA9 TLX3 
LCK  FGFR1 HSP90AB1  JAK3    FGFR1 RARA  LYL1 ZBTB16 
PDGFRA  FIP1L1 NTRK3  PAX3    FLT3 SEPT9    
     TCL1A    HOXC13 SYK    
              
Cell Differentiation Markers 
CD40 PROM1 ADAM17 IL17RA TNFRSF10B DDR1 CD248  PVRL2 CDH1 INSR  FGFR1 TNFRSF1B 
CD81  FGFR1 ITGB3 TNFRSF8 NCAM1 CDH2   CDH2 KDR  IFITM1  
IL10RA  FZD10 MME TNFSF13 TNFRSF8    FGFR1 LAMP3    
KDR  IFITM1 NGFR      FLT3 MME    
PDGFRA  IGF2R       FZD10 MST1R    
         GP1BB THBD    
         ICOSLG     
              
Tumor Suppressors 
EXT2  BRCA1    PHOX2B   BRCA1 WT1  FANCA  
HNF1A         CDH1 XPA    
         HNF1A     
              
 
Table 2.2. Categorization of gene promoters with differentially methylated (DM) PromCpGs in Pa16C, 
Pa01C, PANC-1 and Panc 10.05 cells. The CpG methylation in these four cell lines was the most 
responsive to KRAS depletion. PromCpGs, DM CpGs (i) in a promoter region (200-1500 bases upstream of 
the transcription start site of a gene) and (ii) within 4 kb of a CpG island (including CpGs at shores and 
shelves). 
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2.3.4. Gene ontology analysis of differentially methylated promoters in response 
to KRAS suppression in pancreatic cancer cell lines 
Due to the limited number of overlapping differentially methylated (DM) CpGs 
(Figure 2.4), we attempted to isolate biological processes associated with KRAS 
knockdown that are common between KRAS-depleted cell lines. First, we grouped the 
KRAS-depleted cell lines into “responsive” cells (Pa16C, Pa01C, PANC-1, and Panc 
10.05 cells) and “refractory” cells containing the other 7 pancreatic cell lines in our panel 
(Figure 2.3D). To focus our analysis on genes with DM CpGs most likely to produce 
transcriptional effects, we isolated DM PromCpGs (defined here as a DM CpG in a 
promoter region (200-1500 bases upstream of the transcription start site of a gene) and 
within 4 kb of a CpG island (including shores and shelves). Next, genes containing both 
hypermethylated and hypomethylated PromCpGs within their promoter were excluded. 
Genes encoding transcription factors, oncogenes, kinases, and growth factors showed 
differential DNA methylation at their promoters in KRAS knockdown (Table 2.2). Gene 
ontology analysis was performed using lists of promoters from each KRAS-depleted cell 
line that were hypermethylated or hypomethylated. Then the top ≤20 overlapping 
biological processes were compiled in a heat map (Figure 2.6). The hypermethylated 
promoters in the sensitive/responsive cells were enriched for genes involved in 
development and differentiation (Figure 2.6A); however, the number of 
hypermethylated promoters was significantly reduced in the refractory cells (Table 2.1), 
which limited the number of associated biological processes (Figure 2.6B). The 
hypomethylated promoters in both the responsive cells and the refractory cells were 
enriched for genes involved in development and differentiation, which are shown in bold 
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text (Figure 2.6A-B). The number of biological processes associated with responsive or 
refractory PromCpG methylation in KRAS-depleted cell lines varies based on the cell 
lines and the direction of methylation changes (Figure 2.6C). However, we identified 
seven potentially affected biological processes common among all of the KRAS-
depleted cell lines (Figure 2.6D). Together these results suggest that KRAS 
suppression leads to cell line specific differential DNA methylation of genes involved in 
development and differentiation and corroborates previous gene ontology analyses of 
DM genes in HRAS-transformed fibroblasts, which also showed an enrichment for 
genes involved in development and differentiation (Xie et al., 2018). 
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Figure 2.6. Gene ontology analysis of differentially methylated promoters in KRAS-depleted 
pancreatic cancer cell lines. A. The CpG methylation in these four cell lines was the most responsive to 
KRAS depletion and show the greatest number of differentially methylated (DM) PromCpGs. The gene 
ontology analysis of the hypermethylated (Top) and hypomethylated (Bottom) gene sets from each cell 
line are compared to each other. The biological processes common to all four cell lines are ranked using 
a negative log10 scale of the p-values from the analysis of the Pa16C cells. The top 20 biological 
processes are shown in the heat maps displayed. B. The CpG methylation in these seven cell lines was 
refractory to KRAS depletion and show a reduced number of differentially methylated (DM) PromCpGs. The 
gene ontology analysis of the hypermethylated (Top) and hypomethylated (Bottom) gene sets from each 
cell line are compared to each other. The biological processes common to all seven cell lines are ranked 
using a negative log10 scale of the p-values from the analysis of the Pa04C cells. The top biological 
processes are shown in the heat maps displayed – only 7 common from the hypermethylated (Top) gene 
set. C. Venn diagram showing the number of biological processes associated with responsive or 
refractory PromCpG methylation in KRAS-depleted cell lines. D. List of potentially affected biological 
processes common among all of the KRAS-depleted cell lines. PromCpGs, DM CpGs (i) in a promoter 
region (200-1500 bases upstream of the transcription start site of a gene) and (ii) within 4 kb of a CpG 
island (including CpGs at shores and shelves). 
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2.3.5. DNA methylation changes associated with mutant KRAS overexpression in 
lung cells 
Since our results suggest that KRAS suppression is associated with CpG 
methylation changes in pancreatic cancer cell lines, we hypothesized that the 
overexpression of oncogenic KRAS would also lead to DNA methylation changes. To 
isolate the effects of oncogenic KRAS overexpression, we used an isogenic lung model 
for this experiment. KRAS is mutated in approximately 30% of all lung cancers, making 
lung cells a relevant model to study the effects of activating KRAS mutations. We 
surveyed the CpG methylation patterns in low passage, immortalized lung epithelial 
cells transduced with KRAS G12V (SAKRAS cells) and compared these cells to non-
transformed empty vector controls (SALEB cells). Our analysis showed significantly 
greater DM CpGs in SAKRAS lung cells overexpressing KRAS G12V (50,611 DM 
CpGs) compared to Pa16C pancreatic cells with KRAS knockdown (8,877 DM CpGs). 
Compared to non-transformed SALEB cells, SAKRAS lung cells overexpressing KRAS 
G12V displayed significantly greater hypomethylated CpGs (Figure 2.7A-B). We also 
observed that DNA methylation changes were largely consistent between replicate 
samples. Two of these cell line pairs were treated with exogenous molecules 
(SAKRAS_1 and SALEB_1 with 25 uM siCTL for 48 hours, and SAKRAS_2 and 
SALEB_2 with 0.1% DMSO for 24 hours). However, based on the significant overlap, 
neither treatment discernibly affected the differential methylation patterns in the 
SAKRAS cells. Further categorization of the DM CpGs into “CpG centric” and “gene 
centric” regions reveal the functional distribution of the methylation changes associated 
with KRAS G12V overexpression (Figure 2.7C-D). The mRNA expression 
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corresponding to 6 genes of interest haboring DM CpGs was measured using qRT-PCR 
(Figure 2.7E). Promoter hypermethylation is generally correlated with reduced mRNA 
expression (BRCA1), and hypomethylation with increased expression (NANOG). 
However, the relationship between promoter methylation and transcription always 
requires validation since the above convention is regularly upended - evidenced by 3 
other genes analyzed (HOXA3, HAS1, and WAS) (Figure 2.7E). Although changes at 
individually important CpGs may alter gene expression, alterations to an entire CpG 
region may be better correlated with changes in gene expression (Figure 2.7E, 
BRCA1). The lack of correlation may also be due to the inability of the Infinium 
methylation array to accurately differentiate between 5-methylcytosine and 5-
hydroxymethylcytosine, which could each have different effects on gene expression. 
Taken together, these data suggest that overexpression of oncogenic KRAS G12V is 
associated with significant CpG methylation changes. 
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Figure 2.7. DNA methylation changes associated with mutant KRAS overexpression in lung cells. 
A. Hierarchical Manhattan-Ward clustering analysis was performed with ~450,000 Infinium DNA 
methylation probes for SALEB and SAKRAS cell lines. The top 1000 differentially methylated (DM) CpGs 
by highest absolute beta difference are shown. Each row represents a probe and each column represents 
a sample. The β value (level of DNA methylation) for each probe is represented with a color scale as 
shown in the key. B. Plot showing that CpGs tend to be hypomethylated (median of -0.27664) in the 
SAKRAS cells compared to SALEB cells (50,611 DM CpGs analyzed). C. Categorization of 
hypermethylated (left; yellow) and hypomethylated (right; blue) CpGs in relation to CpG islands (top) and 
gene regions (bottom). D. Diagram showing examples of CpG centric and gene centric regions analyzed 
by the Infinium DNA methylation array. E. Sample list of genes and the corresponding DM CpGs 
observed in SAKRAS cells. The mRNA expression of these genes in SAKRAS cells was measured using 
qRT-PCR. Each colored block represents one DM CpG at the respective region of the stated gene. P, 
promoter region, TSS1500 or TSS200, 1500 or 200 nt upstream of the transcription start site; 5, 5’UTR; 
B, Body, gene body; 3, 3’UTR; Unclassified, undesignated in relation to gene region; Open sea, isolated 
CpGs outside any CpG islands; Shelf, 2 to 4 kb from CpG island; Shore, <2 kb from CpG island. 
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2.3.6. Gene ontology analysis of DM CpGs reveals enrichment of genes involved 
in development and differentiation associated with changes in KRAS expression 
To focus our analysis on genes with DM CpGs most likely to produce 
transcriptional effects in SAKRAS cells overexpressing KRAS G12V, we isolated DM 
PromCpGs (defined here as a DM CpG in a promoter region (200-1500 bases upstream 
of the transcription start site of a gene) and within 4 kb of a CpG island (including 
shores and shelves). The genes with PromCpGs containing both hypermethylated and 
hypomethylated CpGs were excluded. Five hundred and forty-seven genes met these 
conditions, including 196 genes with hypermethylated promoter PromCpGs. Genes 
encoding transcription factors, oncogenes, kinases, and growth factors showed 
differential DNA methylation at their promoters in SAKRAS cells overexpressing KRAS 
G12V (Table 2.3). 
Gene ontology analysis using the list of 196 hypermethylated gene promoters, 
and 351 hypomethylated gene promoters in SAKRAS cells overexpressing KRAS 
G12V, showed an enrichment for genes involved in development and differentiation 
(Figure 2.8), consistent with our previous mutant KRAS loss-of-function studies 
performed in pancreatic cancer cells (Figure 2.6). Gene ontology analysis using the list 
of hypermethylated gene promoters and hypomethylated gene promoters from both 
SAKRAS KRAS G12V expressing cells and Pa16C KRAS knockdown cells, showed the 
common enrichment for genes involved in differentiation and development (Figure 
2.9D-E). It is noteworthy that while mutant KRAS knockdown and overexpression 
ultimately results in DM CpGs of genes involved in similar biological processes, the 
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specific number and composition of gene loci affected are distinct and unique to each 
cell line. Taken together, these data suggest that mutant KRAS overexpression is 
associated with greater changes in DNA methylation compared to KRAS suppression. 
In addition, although the lists of DM genes affected by changes in KRAS expression 
may be distinct between cell lines, they showed an enrichment for genes involved in 
development and differentiaion. 
To directly assess the role of mutant KRAS in maintaining DNA methylation 
patterns in the isogenic lung model, we also isolated the differentially methylated (DM) 
CpGs from SAKRAS cells transfected with KRAS siRNA and compared these to cells 
transfected with control siRNA (Figure 2.9A-B). Here, we observed 86 DM CpGs in 
SAKRAS cells containing siRNA targeting KRAS (Figure 2.9B). Interestingly, only 2 of 
these CpGs were also DM in the SAKRAS vs SALEB cell comparison (Figure 2.9B, 
Left). This included LRRC7 and the pluripotency transcription factor, NANOG, which 
were both hypomethylated in SAKRAS cells compared to SALEB cells, and then 
hypermethylated when KRAS was depleted via siRNA (Figure 2.9A-B). These data 
suggest that KRAS overexpression leads to significantly greater DM CpGs compared to 
KRAS suppression. 
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SAKRAS cells 
Hyper- 
methylated 
Hypo- 
methylated 
Transcription Factors 
BARHL2 HOXA5 AFF2 OTX1 
BARX2 IRX1 BRDT PAX2 
C11orf9 IRX3 CITED1 PAX9 
CDX1 KEAP1 CRIP1 SALL1 
CDX2 KLF11 ELF4 SIM2 
CTNNB1 MYBL2 EMX1 SNAPC2 
ETV7 NKX2-3 FOXC2 SOX1 
FEZF2 NKX6-2 FOXG1 SOX11 
FHL2 PAX7 FOXO4 SOX3 
FOXA2 POU3F2 GSC TAF1 
GATA5 PRDM2 HEYL TBX1 
GBX2 SOX21 HIC1 TBX2 
HAND1 TBX3 HOXA9 TBX4 
HES5 ULK2 HSF4 TLX2 
HES6 UNCX ISL2 TSC22D3 
HHEX UTF1 LHX2 ZFP161 
HNF1B VAX1 LMX1A ZIC3 
HOXA2 ZIM2 NFYB ZNF132 
  NKRF ZNF318 
  OLIG2 ZNF630 
    
Cytokines & Growth Factors 
APLN  ADM2 NGF 
CMTM2  EDN3 NPY 
FGF22  FGF13 OXT 
NPPC  GAL STC2 
PYY  GDF7  
    
Homeodomain Proteins 
BARHL2 IRX1 EMX1  
BARX2 IRX3 GSC  
CDX1 NKX2-3 HOXA9  
CDX2 NKX6-2 ISL2  
GBX2 PAX7 LHX2  
HHEX POU3F2 LMX1A  
HNF1B UNCX OTX1  
HOXA2 VAX1 PAX2  
HOXA5  TLX2  
    
Protein Kinases 
CSNK1D  BRDT MST4 
EPHA8  CDKL5 PDK3 
FLT1  FASTK RPS6KA3 
GUCY2D  IRAK3 TAF1 
STK32C  MAPK4  
ULK2    
    
Oncogenes 
CDX2  ELF4 MSI2 
CTNNB1  FOXO4 OLIG2 
FEV  GNAS SEPT9 
PAX7  HOXA9 TCL1A 
    
Cell Differentiation Markers 
FUT4  CD151  
GP1BB  CD8A  
  IL13RA1  
  PTPRJ  
    
Tumor Suppressors 
BRCA1  FAM123B  
    
 
Table 2.3. Categorization of gene promoters with differentially methylated (DM) PromCpGs associated with 
KRAS overexpression in SAKRAS lung cell line. PromCpGs, DM CpGs (i) in a promoter region (200-1500 
bases upstream of the transcription start site of a gene) and (ii) within 4 kb of a CpG island (including 
CpGs at shores and shelves). 
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Figure 2.8. Gene ontology analysis of differentially methylated promoters associated with KRAS 
G12V overexpression in lung cells. The gene ontology analysis of the hypermethylated (Top) and 
hypomethylated (Bottom) gene sets from the SAKRAS lung cell line are ranked using a negative log10 
scale of the p-values. The top 20 biological processes are shown in the heat maps displayed. Biological 
processes involved in cell development and differentiation shown in bold. 
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Figure 2.9. Gene ontology analysis of DM CpGs reveals enrichment of genes involved in 
development and differentiation associated with changes in KRAS expression. A. Western blot 
showing KRAS protein expression in SAKRAS cells transfected with siRNA targeting KRAS. B. Limited 
differential CpG methylation with KRAS knockdown in SAKRAS cells. Heat map showing the Δβ values 
(level of DNA methylation) of all the DM CpGs in SAKRAS cell transfected with siRNA targeting KRAS. 
Δβ values in column labeled siCTL are relative to SALEB control cells. C. Differentially methylated CpGs 
that changed in opposite directions in SAKRAS vs SALEB cells compared to Pa16C KRAS shRNA vs 
Pa16C NS shRNA. D-E. Gene ontology analysis of gene promoters that are hypermethylated and 
hypomethylated in the respective cell lines. Heat map of the top 20 overlapping biological processes, 
sorted by -log10 scale of p-values in the left column of each comparison, and showing a large number of 
biological processes involved in cell development and differentiation. 
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2.4. DISCUSSION 
2.4.1. DNA methylation associated with mutant KRAS expression 
The KRAS gene is one of the most commonly mutated genes in cancer. This 
small GTPase and its effectors control key aspects of cancer development. However, 
attempts to directly target oncogenic KRAS have been unsuccessful. In addition to 
aberrant signaling, the expression of mutant KRAS is correlated with global differential 
DNA methylation. Therefore, epigenetic changes associated with oncogenic KRAS 
expression could be an avenue where the survival of KRAS-dependent cancer cells 
may be vulnerable. Here we describe the differential DNA methylation associated with 
the knockdown and overexpression of oncogenic KRAS in pancreatic and lung cells. 
We analyzed the DNA methylation profiles in a panel of KRAS mutant pancreatic cancer 
cells and observed strikingly similar patterns (Figure 2.2). To determine whether these 
methylation patterns are stable, or dependent on KRAS expression, we silenced KRAS 
the panel of pancreatic cancer cell lines using shRNA (Figure 2.3). Although the basal 
DNA methylation patterns of the control cells are similar, the differential DNA 
methylation associated with KRAS knockdown showed patterns unique to each cell line. 
To determine whether the effects of KRAS knockdown are ERK-dependent, Pa16C 
cells were treated with the ERK inhibitor SCH772984 (Figure 2.5). Interestingly, we 
observe <40 DM CpGs with ERK inhibition compared to >8,000 DM CpGs with KRAS 
shRNA in the Pa16C cells. Finally, to identify differential DNA methylation associated 
with mutant KRAS overexpression, we compared immortalized KRAS G12V 
transformed lung epithelial SAKRAS cells to non-transformed SALEB controls. In the 
lung epithelial cells, a great number of DM CpGs correlated with the overexpression of 
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KRAS G12V (>50,600 DM CpGs) (Figure 2.7) compared to KRAS suppression in 
pancreatic cells (Figure 2.3) or SAKRAS cells (Figure 2.9A-B). Together, these data 
suggest that the majority of differential DNA methylation associated with KRAS 
knockdown is cell-specific. KRAS depletion using shRNA yields greater DM CpGs 
compared the ERK inhibitor treatment, suggesting that the loss of KRAS affects the 
methylation profile in an ERK-independent manner. Furthermore, KRAS overexpression 
is associated with a greater number of DM CpGs compared to KRAS suppression. 
 
2.4.2. Cell specific differential DNA methylation 
Although the basal DNA methylation patterns of the pancreatic cancer cell lines 
are similar (Figure 2.2), the differential DNA methylation associated with KRAS 
knockdown showed patterns unique to each cell line. The number of DM CpGs ranges 
from dozens to thousands depending on the cell line (Figure 2.3D and Table 2.1). 
Moreover, we only observed 204 DM CpGs common in at least 3 of the pancreatic 
knockdown cells, and none of these DM CpGs were shared between more than 4 of the 
10 cell lines (Figure 2.4). This suggests a cell line specific epigenetic response to 
KRAS depletion and that the methylation profile of some cells may be more vulnerable 
to KRAS knockdown than others (Figure 2.3D). A number of studies suggest that the 
majority of the differential DNA methylation associated with cancer may be stochastic in 
nature - contributing to low levels of overlap and high heterogeneity between cell lines 
(even when they share the same genetic background and/or origin) (Burga et al., 2011; 
Feinberg, 2014; Hanna et al., 2009; Landan et al., 2012; Raj and van Oudenaarden, 
2008; Xie et al., 2018). Whereas, our studies show similar methylation patterns between 
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9 of 11 pancreatic cell lines (Figure 2.2), which could suggest a non stochastic model; 
however, the influence of cell state and cell lineage may largely determine the patterns 
observed. The majority of the DM CpGs observed in this study appear to be specific to 
each cell line. The proapoptotic gene FAS has been reported to undergo HRAS-
mediated epigenetic silencing in fibroblasts (Gazin et al., 2007); however, this was not 
observed in the panel of pancreatic cell lines (Table 2.2 and Supplementary Table 
2.4). The epigenetic silencing of the IRAK3 gene has also been reported in KRAS 
mutant cells and other tissues (De Carvalho et al., 2012), but again, this was not 
observed in the panel of pancreatic cell lines. Therefore, certain DNA methylation 
events, which may be critical for survival in certain cell lines, may be inconsequential in 
others. Although, many of these DNA methylation changes could be stochastic in nature 
and simply “passenger” events, or a consequence of their cell state and cell lineage, 
KRAS is likely still able to influence key changes to the epigenome that are ultimatley 
crucial for the cancer phenotype. More studies are needed to determine whether 
stratification will produce correlations strong enough to permit the prediction of cancer 
subtypes based on the methylation patterns or vice versa. 
 
2.4.3. KRAS effector mediated differential DNA methylation 
Another interesting observation is the difference between the number of DM 
CpGs associated with KRAS knockdown and KRAS overexpression - there are 
significantly less DM CpGs associated with KRAS suppression. KRAS remains crucially 
linked to cell proliferation through ERK, its main effector, and inhibition of this pathway 
reliably leads to growth arrest (Figure 2.5) (Hayes et al., 2016). However, the question 
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remains, if not ERK, which KRAS effectors are leading to the thousands of DNA 
methylation changes we observe (Figure 2.3D). In mouse lung adenocarcinoma cells, 
YAP1 was able to rescue KRAS depleted cells, suggesting a relevant mechanism to 
bypass loss of KRAS signaling (Shao et al., 2014). In the same study, KRAS also 
induces PI3K expression, and yet, the subsequent suppression of KRAS has no effect 
on the upregulated AKT activation. PI3K has been shown to compensate for KRAS 
suppression in pancreatic cancer cells and regulate epigenetic modifiers including 
DNMTs (Fagnocchi et al., 2016). KRAS knockdown cells display sensitivity to PI3K 
inhibitors and dual PI3K and MEK inhibitors have been found to be more effective than 
blocking the individual pathways alone (Muzumdar et al., 2017). If proteins such as 
YAP1 and PI3K play a role downstream of KRAS to induce epigenetic changes, this 
could explain why significantly less DM CpGs are associated with KRAS suppression 
compared to overexpression. A KRAS effector pathway such as PI3K, which is 
upregulated upon mutant KRAS expression, could be responsible for many of the 
methylation changes observed. The majority of differential DNA methylation associated 
with KRAS expression could be mediated by effector pathways similar to PI3K that are 
refractory to KRAS suppression, while a minority would be directly dependent on KRAS 
signaling. Upon KRAS suppression, sustained PI3K activity may be able maintain the 
majority of methylation changes induced by mutant KRAS. This kind of sustained 
activity by effector pathways could maintain the methylation status of the majority of the 
changes initially induced by mutant KRAS expression (Figure 2.10). This would explain 
why such a modest number of CpGs are DM in response to KRAS suppression. 
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Figure 2.10. Hypothetical model showing epigenetic regulation of developmental genes by mutant 
KRAS. Activating KRAS mutations lead to persistant induction of effector pathways that drive the cancer 
phenotype including the differential DNA methylation of genes involved in development and 
differentiation. In some cell lines, effector pathways such as PI3K and others, are able to maintain their 
abberant activity independent of KRAS signaling. As a consequence of feed forward loops initiated by 
mutant KRAS, kinome reprogramming, or the establishment of stable epigenetic patterns, the majority of 
DNA methylation changes associated with mutant KRAS activity remains refractory to KRAS suppression. 
However, independent of the changes in DNA methylation, KRAS knockdown and ERK inhibition still both 
lead to growth arrest in KRAS driven cell lines. SCH772984, type I and type II ERK inhibitor. 
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Once cells have been transformed and DNA methylation changes have been 
established following mutant KRAS expression, the large majority of these changes may 
no longer be tied to the presence or absence of KRAS activity, even as the cell’s growth 
and survival are still tied to KRAS expression. DNA methylation profiling in the presence 
of a PI3K inhibitor could shed light on these questions, along with how reversion of the 
KRAS-induced methylation changes can affect cell state and cell differentiation. 
 
2.4.4. Differential DNA methylation of genes involved in differentiation and 
development 
Many of the DM CpGs associated with KRAS overexpression in our study are 
located at the promoters of important tumor suppressors, oncogenes, transcription 
factors, and regulators of differentiation (Table 2.3). Moreover, gene ontology analysis 
revealed an enrichment for differentially methylated genes involved in differentiation and 
development (Figure 2.8). The regulation of pluripotency and lineage-specific genes 
require the integration of multiple signaling pathways, epigenetic modifiers, and 
transcription factors (Wang et al., 2017). In response to KRAS suppression, KRAS-
driven cells may rely on compensatory survival pathways such as the PI3K pathway. 
PI3K/AKT has been shown to affect the expression of differentiation and stemness 
genes. In our pancreatic KRAS knockdown cells, a number of these genes appear to be 
differentially methylated in response to KRAS suppression (Table 2.2). In Pa16C cells, 
for example, the promoter of FGF9, a gene reported to activate AKT signaling, is 
hypomethylated (Lai et al., 2014; Sun et al., 2015). The promoter of NRG3, a ligand that 
activates HER3, an EGFR member of receptor tyrosine kinase (RTK) signaling 
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upstream of PI3K/AKT, is hypomethylated (Mujoo et al., 2014). The promoter of GDNF, 
which can also activate PI3K, is hypomethylated. POU3F2 and OLIG2 were both 
hypomethylated - two out of the four genes, from a core set of neurodevelopmental 
transcription factors (POU3F2, SOX2, SALL2, and OLIG2) essential for GBM 
propagation. These transcription factors coordinately bind and activate regulatory 
elements sufficient to fully reprogram differentiated GBM cells into tumor propagating 
stem-like cells (Suvà et al., 2014). Another promoter hypomethylated upon KRAS 
knockdown is HOXA9, a major transcription factor that regulates stem cells during 
development. Aberrant expression of HOX genes occurs in various cancers, and 
HOXA9 transcriptomes are specifically associated with cancer stem cell features 
(Seifert et al., 2015). Hypomethylated PromCpGs were also found at the BMP3 promoter. 
BMPs are implicated in activation of signaling pathways that drive epithelial-
mesenchymal transition (EMT), including WNT signaling, TGFB signaling and PI3K 
signaling, all important pathways in pancreatic cancer cells (McCormack et al., 2013; 
Shao et al., 2014; Zabkiewicz et al., 2017). And finally, another promoter which 
appeared as hypomethylated was TWIST1, a canonical EMT transcription factor shown 
to promote cancer stem cell properties (Mani et al., 2008). Overexpression of TWIST1 is 
reported to override Myc-induced apoptosis in tumor cells and along with the other 
changes, could be a compensatory response by the Pa16C KRAS mutant pancreatic 
cells to survive KRAS suppression. In the study by Shao et al., the authors looked for 
transcriptional programs regulated by both KRAS and YAP1 in microarray data and 
found the top gene sets enriched included several related to differentiation and 
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development, similar to what we found with our gene ontology analysis (Shao et al., 
2014) (Figure 2.6). 
Together, our findings suggest that oncogenic KRAS expression is associated 
with differential DNA methylation and KRAS overexpression may affect a greater 
number of CpGs compared to KRAS knockdown due to sustained activity of KRAS 
effector pathways even in KRAS knockdown cells. This would explain why we observe 
such a discrepancy between the high number of DM CpGs correlated with KRAS 
overexpression compared to the modest changes we see with KRAS knockdown. This 
study describes the differential DNA methylation associated with oncogenic KRAS 
expression and suggests that although these methylation changes are cell specific, the 
biological processes that are impacted may overlap. If the DNA methylation profile in 
these cells are susceptible to KRAS depletion, gene promoters involved in development 
and differentiation appear to be consistently impacted. This has been explored in 
previous studies (Xie et al., 2018) and may be an avenue deserving of more work in the 
search for supplementary strategies to target KRAS-driven cancers. 
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2.5. MATERIALS AND METHODS 
Cell Culture 
PDAC cell lines were obtained from ATCC and were maintained in Dulbecco’s Modified 
Eagle Medium supplemented with 10% fetal calf serum (FCS) (HPAC and PANC-1), in 
RPMI 1640 supplemented with 10% FCS (CFPAC-1, HPAF-II, Panc 10.05, and SW-
1990). Low passage SALEB and SAKRAS cells were generous gifts from Dr. Scott H. 
Randell (UNC-Chapel Hill) and were grown as described previously (Lundberg et al., 
2002). The SALEB cells were generated by infecting small airway lung epithelial cells 
with an amphotropic retrovirus that transduces SV40 ER, which encodes both the LT 
and small t antigens, and a neomycin drug resistance marker. These cells were 
subsequently infected with a retrovirus vector that transduces the hTERT gene together 
with the hygromycin resistance marker. Expression of these genetic elements was 
sufficient to immortalize the SALEB* cells. Finally, SALEB* cells were infected with 
retrovirus that transduces (i) the puromycin resistance marker (SALEB) or (ii) mutant 
KRAS G12V oncogene together with the puromycin resistance marker (SAKRAS). All 
other cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM; Gibco) 
supplemented with 10% fetal bovine serum (FBS; EMD Millipore). Cell lines were used 
for no longer than 6 months before being replaced. Stable cell lines were generated by 
selection in 2ug/ml puromycin. 
 
Western Blot Reagents 
Cells were lysed in 1% NP-40 lysis buffer (phosphatase and protease inhibitors from 
Sigma-Aldrich added fresh). Protein extracts were quantified by Bradford assay (Bio-
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Rad Laboratories) and analyzed by SDS-PAGE. Blot analyses were done with phospho-
specific antibodies to ERK1/2 (T202/Y204) and antibodies recognizing total ERK1/2 to 
control for total protein expression. Antibody to KRAS4B was obtained from 
Calbiochem. Antibody for β-actin was used to verify equivalent loading of total cellular 
protein. Antibodies were purchased from Cell Signaling Techonology unless otherwise 
stated.  
 
Small Molecule Inhibitors 
The ERK1/2-selective inhibitor SCH772984 was synthesized at Merck. Inhibitors for in 
vitro studies were dissolved in dimethyl sulfoxide (DMSO) to yield a 10 mM or 20 mM 
stock concentration and stored at -20 or -80°C, respectively. 
 
siRNA and shRNA Transfection Reagents 
The following human siRNA (siGenome SMARTpool) was purchased from Dharmacon 
as a pool of four annealed dsRNA oligonucleotides: KRAS (L-005069–00) and non-
targeting control #3 (D-001210-03). Dharmafect transfection reagent 1 was used to 
transfect 20-40nM siRNA according to manufacturer’s instruction and cells were 
harvested 96 hours after transfection. The target sequence for the validated shRNA 
construct used to target KRAS was CAGTTGAGACCTTCTAATTGG. The lentivirus 
vector encoding shRNA targeting KRAS (TRCN0000010369) was provided by J. 
Settleman (Genentech). Target cells were transduced by combining viral particle-
containing medium with complete media at a ratio of 1:4 in the presence of polybrene (8 
µg/ml). Media were exchanged 8-10 h later and selection was initiated following 16 h 
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incubation in complete media. Samples were collected 72-120 h after the initiation of 
selection. 
 
DNA Methylation Analysis 
Global DNA methylation was evaluated using the Infinium HumanMethylation450 
BeadChip Array (Illumina, San Diego, CA). 1 μg of each DNA sample underwent 
bisulfite conversion using the EZ DNA Methylation Kit (Zymo Research, Irvine, CA) 
according to the manufacturer’s recommendation for the Illumina Infinium Assay. 
Bisulfite-treated DNA was then hybridized to arrays according to the manufacturer’s 
protocol. We used GenomeStudio V2011.1 (Illumina) for methylation data assembly and 
acquisition. Methylation levels for each CpG residue are presented as β values, 
estimating the ratio of the methylated signal intensity over the sum of the methylated 
and unmethylated intensities at each locus. The average β value reports a methylation 
signal ranging from 0 to 1, representing completely unmethylated to completely 
methylated values, respectively. Methylation data was preprocessed using the DMRcate 
package (Peters et al., 2015). Data preprocessing included background correction, 
probe scaling to balance Infinium I and II probes, quantile normalization, and logit 
transformation. A logit transformation converts otherwise heteroscedastic beta values 
(bounded by 0 and 1) to M values following a Gaussian distribution. Additionally, 
detection p-values >0.05 in 25% of samples, probes on X and Y chromosomes, and 
probes situated within 10 bp of putative SNPs were removed. Differential methylation 
analysis on logit-transformed values was performed to compare samples in IMA. Wilcox 
rank test was conducted between experimental and control samples and p-values were 
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corrected by calculating the false discovery rate by the Benjamini-Hochberg method. 
Probes with adjusted p-values <0.05, and delta β values ≥0.2 or ≤-0.2 to 4 significant 
figures are considered statistically significant and differentially methylated. The 
methylation data discussed in this publication have been deposited in NCBI's Gene 
Expression Omnibus and are accessible at 
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE119548. The ENCODE 
methylation data used in this publication were retrieved from the ENCODE Data 
Coordination Center and are accessible at https://www.encodeproject.org/ucsc-browser-
composites/ENCSR037HRJ. 
 
RNA Sequencing and Analysis 
RNA sequencing was performed as described in Bryant et al., (Nature Medicine, In 
Review). Briefly, a panel of human PDAC cell lines was infected with lentiviral vectors 
encoding shRNA targeting KRAS or a scrambled control construct for 8-10 h, and then 
selected for 48-96 h (depending on cell line). Following selection, cells were washed 
twice in ice cold phosphate-buffered saline (PBS), scraped in ice cold PBS, collected by 
centrifugation, and flash frozen. Total RNA (50 ng) for the pancreatic cell lines was used 
to generate whole transcriptome libraries for RNA sequencing using Illumina's TruSeq 
RNA Sample Prep. Poly-A mRNA selection was performed using oligo(dT) magnetic 
beads, and libraries were enriched using the TruSeq PCR Master Mix and primer 
cocktail. Amplified products were cleaned and quantified using the Agilent Bioanalyzer 
and Invitrogen Qubit. The clustered flowcell was sequenced on the Illumina HiSeq 2500 
for paired 100-bp reads using Illumina's TruSeq SBS Kit V3. Lane level fastq files were 
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appended together if they were sequenced across multiple lanes. These fastq files were 
then aligned with STAR 2.3.1 to GRCh37.62 using ensembl.74.genes.gtf as GTF files. 
Transcript abundance was quantified and normalized using Salmon in the unit of 
transcripts per million (TPM). Clustering was performed using R heatmap.2 package 
with Euclidean Distance and McQuitty clustering method. Binary sequence 
alignment/map (BAM) files of RNA-seq data is available from the EMBL-EBI European 
Nucleotide Archive (ENA) database - http://www.ebi.ac.uk/ena/ with accession number 
PRJEB25797 The data is accessible 
via http://www.ebi.ac.uk/ena/data/view/PRJEB25797. The sample accession number is 
ERS2363485-ERS2363504. 
 
Gene Ontology Analysis 
The differentially methylated (DM) CpGs (i) in a promoter region (200-1500 bases 
upstream of the transcription start site of a gene) and (ii) within 4 kb of a CpG island 
(including CpGs at shores and shelves) are referred to as PromCpGs in this study. If a 
gene contains PromCpGs that did not all change in the same direction (all 
hypermethylated or all hypomethylated), that gene was excluded from analysis. Gene 
sets with hypermethylated or hypomethylated PromCpGs are loaded into Molecular 
Signature Database (MSigDB) (Subramanian et al., 2005) 
(http://www.broad.mit.edu/gsea/) and members of each gene set are categorized by 
gene families (Supplementary Table 2.4). The gene ontology analyses were generated 
using IPA (QIAGEN Inc., https://www.qiagenbioinformatics.com/products/ingenuity-
pathway-analysis) (Krämer et al., 2014). The gene set of interest was uploaded into IPA 
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(Ingenuity Systems, Redwood City, CA) and the Core Analysis workflow was run with 
default parameters. The Core Analysis provides an assessment of significantly altered 
pathways, molecular networks, and biological processes represented in the samples' 
gene list. The relative ranking order of biological processes were determined using a 
negative log10 scale of their p-values (Supplementary Table 2.5). The most enriched 
(top 20) biological processes with p-value < 0.01 were picked. The gene sets used for 
analysis either contained hypermethylated PromCpGs only or hypomethylated PromCpGs 
only. Individual promoters with both hypermethylated and hypomethylated PromCpGs 
were excluded from gene set enrichment analysis. 
 
2.6. SUPPLEMENTARY INFORMATION 
Supplementary Table 2.4. Categorization of gene promoters with differentially 
methylated (DM) PromCpGs in all KRAS-depleted pancreatic cancer cell lines, 
supplementing Table 2.2. PromCpGs, DM CpGs (i) in a promoter region (200-1500 bases 
upstream of the transcription start site of a gene) and (ii) within 4 kb of a CpG island 
(including CpGs at shores and shelves). This is a supplemental spreadsheet. 
Supplementary Table 2.5. Gene ontology analysis of differentially methylated 
promoters in KRAS-depleted pancreatic cancer cell lines. The CpG methylation in 
Pa16C, Pa01C, PANC-1, and Panc 10.05 cells was the most responsive to KRAS 
depletion and show the greatest number of differentially methylated (DM) PromCpGs. The 
gene ontology analysis of the hypermethylated and hypomethylated gene sets from 
each cell line are compared to each other. The biological processes common to all four 
cell lines are ranked using a negative log10 scale of the p-values. The CpG methylation 
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in the other seven cell lines was refractory to KRAS depletion and show a reduced 
number of differentially methylated (DM) PromCpGs. The gene ontology analysis of the 
hypermethylated and hypomethylated gene sets from each cell line are compared to 
each other. The biological processes common to all seven cell lines are ranked using a 
negative log10 scale of the p-values. This is a supplemental spreadsheet for Figure 2.6. 
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CHAPTER III: INVESTIGATING THE ROLE OF RELB IN 
KRAS MUTANT CANCER CELLS1 
3.1. OVERVIEW 
The NF-κB pathway contributes to cellular transformation in KRAS-driven cancer. 
Here, we aim to uncover novel effects of the noncanonical NF-κB pathway in KRAS 
mutant cells and better understand the role of the NF-κB transcription factor subunit, 
RELB. Our findings suggest that RELB expression is upregulated in KRAS mutant cells 
in vitro and in vivo. Interestingly, in previous DNA methylation studies, we also observed 
hypomethylation at the RELB promoter in cells expressing KRAS G12V. In lung and 
pancreatic cancer cell lines expressing mutant KRAS, RNAi against RELB decreases 
proliferation and nonadherent colony growth. However, depletion of RELB did not show 
significant effects on proliferation in murine xenograft and genetic models. Models 
designed to assess migration, metastasis, and cell-state transitions associated with 
RELB expression could yield more actionable results in future studies. Together, these 
results suggest that mutant KRAS leads the upregulation of RELB expression, and 
supports an important role for the noncanonical NF-κB pathway as a potential 
therapeutic target in KRAS-driven malignancies. 
  
                                                        
1 The following authors contributed to this study: Joel K. Durand, Aaron Ebbs, Nancy Kren, Yuliya 
Pylayeva-Gupta and Albert S. Baldwin 
 91 
3.2. INTRODUCTION 
The NF-κB family of transcription factors consists of five structurally-related 
protein subunits that share affinity for the κB DNA sequence motif (Ghosh et al., 1998; 
Kunsch et al., 1992; Pierce et al., 1988). This family of proteins can be divided into two 
classes; the NF-κB proteins (p105/p50 or NFKB1 and p100/p52 or NFKB2) and the Rel 
proteins (c-Rel, RelB, and RelA/p65) (Gilmore, 1999a). Through proteasome-mediated 
proteolysis, p105 and p100 are processed into the shorter DNA-binding subunits called 
p50 and p52, respectively (Betts and Nabel, 1996; Fan and Maniatis, 1991). The Rel 
proteins are distinguished by C-terminal transcriptional activation domains (TAD) 
(Schmitz and Baeuerle, 1991), while all five NF-κB/Rel subunits contain the N-terminal 
Rel homology domain (RHD), essential for DNA binding, dimerization, Inhibitor of κB 
(IκB) interaction, and nuclear localization (Chen and Ghosh, 1999; Urban and Baeuerle, 
1990). 
The canonical NF-κB transcription factor is a dimer composed of a p50 and 
RelA/p65 subunit, which largely resides in the cytoplasm as part of a latent complex 
with IκBα under basal conditions (Baeuerle and Baltimore, 1988a; 1988b). This highly 
inducible pathway is activated by intracellular or extracellular signals such as tumor 
necrosis factor alpha or TNF-α, interleukin-1 or IL-1, lipopolysaccharide (LPS), viral 
double stranded RNA, and ionizing radiation (Brach et al., 1991; Chow et al., 1999; Gil 
et al., 2000; Hoshino et al., 1999; Osborn et al., 1989). Pathway activation leads to 
induction of the Inhibitor of κB kinase (IKK) complex comprised of the two catalytic 
subunits IKKα and IKKβ, and one scaffold subunit called nuclear factor κB essential 
modulator (NEMO) or IKKγ (Chen et al., 1996; DiDonato et al., 1997; Mercurio et al., 
 92 
1997; Rothwarf et al., 1998; Yamaoka et al., 1998). IκBα is phosphorylated at serine 32 
and 36 by the IKK complex (Brown et al., 1995; Traenckner et al., 1995; Whiteside et 
al., 1995), polyubiquitinated (Chen et al., 1995; DiDonato et al., 1996; Scherer et al., 
1995) and degraded by the proteasome (Miyamoto et al., 1994; Whiteside et al., 1995). 
The degradation of IκBα consequently frees the canonical NF-κB dimer, p50-RelA/p65, 
to translocate into the nucleus and activate gene transcription (Antonaki et al., 2011; 
Miyamoto et al., 1994). 
Although the canonical NF-κB pathway has been more extensively studied, the 
noncanonical pathway is important within certain contexts (Dejardin, 2006). Activation of 
the “alternative” pathway begins with the induction of TNF receptor (TNFR) family 
members such as lymphotoxin-beta receptor or LTβR (Dejardin et al., 2002), receptor of 
B cell-activating factor belonging to the TNF family or BAFF-R (Claudio et al., 2002; 
Kayagaki et al., 2002), receptor activator of NF-κB (RANK) (Novack et al., 2003) and 
cluster of differentiation 40 (CD40) (Coope et al., 2002). Upon receptor activation, TNF 
receptor associated factor (TRAF) proteins mediate the activity of NF-κB inducing 
kinase (NIK) (Liao et al., 2004), which activates an IKKα homodimer (Ling et al., 1998; 
Senftleben et al., 2001) leading to p100 processing into the active p52 subunit (Xiao et 
al., 2004). Ultimately, processing of p100 results in the generation of the noncanonical 
transcription factor, a p52-RelB dimer, which is then able to move onto available κB 
DNA-binding sites and control expression of its associated genes (Bonizzi et al., 2004). 
In addition to regulating immune responses, the NF-κB family of transcription 
factors also promotes cellular proliferation and survival. NF-κB and its activating kinase, 
IKK, have become appealing therapeutic targets because of their critical roles in the 
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progression of many diseases including chronic inflammation and cancer. Previously, 
our lab has shown that knocking out the p65 subunit of NF-κB significantly reduces 
tumor development in a mouse model of KRAS-induced lung cancer. More recent 
evidence has shown that both canonical and noncanonical NF-κB pathways can 
promote oncogenesis (Bang et al., 2013; Kendellen et al., 2014; Rinkenbaugh et al., 
2016). In ER-negative basal-like breast cancer cells, EZH2 interacts with RelA/p65 and 
RelB to confer constitutive activation of NF-κB target gene expression independent of its 
histone methyltransferase activity. This appears to be context-dependent, since EZH2 
represses NF-κB target genes in ER-positive luminal-like breast cancer cells (Lee et al., 
2011). Our group has shown that EZH2, through a methyltransferase-independent 
mechanism, promotes the transcriptional activation of RelB to drive self-renewal and the 
tumor initiating cell phenotype of triple-negative breast cancer cells (Lawrence and 
Baldwin, 2016). 
Here, we aim to uncover novel effects of the noncanonical NF-κB pathway in 
KRAS mutant cells and better understand the role of the NF-κB transcription factor 
subunit, RELB. 
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3.3. RESULTS 
3.3.1. RELB is upregulated in KRAS transformed cells 
The canonical NF-κB transcription factor, RELA, has been well established as an 
important protein required for KRAS transformation (Bassères et al., 2010; Meylan et 
al., 2009). However, the role of the noncanonical transcription factor subunit, RELB, in 
KRAS mutant cancer cells is not fully understood. To determine the importance of RELB 
in KRAS mutant cells, we first measured RELB expression in a mouse model of KRAS 
mutant lung adenocarcinoma (DuPage et al., 2009). This mouse model contains 
“floxed” alleles of KRAS fl/+ and p53 fl/fl. Following aspiration of an adeno-Cre virus into 
their lungs, the KRAS G12D transgene is expressed and the p53 alleles are 
simultaneously deleted. After roughly 12 weeks, mice were harvested for lung tumors. 
Interestingly, RELB expression is increased in KRAS G12D mutant lung tumors relative 
to the normal lung tissue (Figure 3.1A). Next, we measured RELB expression in an 
human lung epithilial cell line, comparing KRAS G12V transformed (SAKRAS) cells to 
isogenic nontransformed (SALEB) cells (Figure 3.1B). Again, increased RELB 
expression is observed in KRAS transformed cells, while KRAS knockdown reduces 
RELB expression to basal mRNA levels. This suggests that RELB expression is 
upregulated in KRAS transformed cells, and suggests a funtion for this transcription 
factor in KRAS transformed cells. 
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Figure 3.1. RELB is upregulated in KRAS transformed cells. A. Western blot showing RELB protein 
expression in normal and tumor lung tissue from a mouse model for KRAS driven lung cancer. Lungs 
were harvested, normal and tumor tissue was isolated, and samples were processed for protein analysis. 
The murine model contains an oncogenic G12D mutation in the KRAS gene’s endogenous locus. To 
control the expression of KRAS G12D, a lox-stop-lox (LSL) cassette is engineered into the first intron of 
the KRAS gene. The LSL cassette consists of transcriptional and translational stop elements flanked by 
LoxP sites that prevents the expression of the mutant allele until the stop elements are removed by Cre 
recombinase. The LSL cassette thus creates a null version of the gene. KRAS null mice are embryonic 
lethal; therefore, mice can only be heterozygous for the KRAS-LSL-G12D allele (DuPage et al., 2009). To 
mimic the loss of p53 function in our KRAS-LSL-G12D-driven tumor model, a ‘floxed’ p53 allele (p53fl) 
has LoxP sites flanking exons two through ten of p53 that are deleted after Cre-mediated recombination, 
abolishing p53 function. Prior to Cre-mediated recombination, the p53 locus is maintained in its wild type 
state and p53 activity is normal (DuPage et al., 2009). B. (Left) Relative mRNA expression in siRNA 
treated SALEB and SAKRAS lung epithelial cells as measured by qRT-PCR. Expression normalized to 
SALEB siCTL sample. Cells were harvested 96 hours post siRNA transfection. (Right) Western blot 
showing basal RELB protein expression in SALEB and SAKRAS cells. 
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3.3.2. RELB knockdown inhibits cell proliferation in KRAS transformed cells 
To determine the role of RELB in the proliferation of KRAS transformed cells, we 
transiently silenced RELB expression using siRNA. We also compared the effects of 
RELB depletion to the suppression of KRAS and other NF-κB transcription factor 
subunits, RELA and NFKB2 (encodes precursor of RELB binding partner p52). The 
canonical and noncanonical subunits both inhibited cell proliferation at comparable 
levels in the KRAS transformed (SAKRAS) cells (Figure 3.2A). The NFKB2 gene 
encodes the gene product p100, which is post-translationally processed into the dimer 
partner for the RELB/p52 noncanonical transcription factor (TF). The growth 
suppression observed with RELB depletion is recapitulated with the suppression of its 
binding partner, p52. This suggests that the effects on proliferation observed in vitro are 
due to the noncanonical RELB/p52 transcription factor and not different RELB 
heterodimer. Interestingly, RELA suppression leads to a decrease in RELB expression, 
which supports a mechanism where RELA regulates the transcription of the 
noncanonical subunit (Figure 3.2B). The canonical subunit RELA/p65, has been well 
established as an important mediator for KRAS mutant cell survival and proliferation. 
The RELA-dependent expression of RELB we observed (Figure 3.2B), suggests that 
some of the outcomes attributed to RELA, may be more closely connected to the 
expression and function of the noncanonical TF, RELB. Together these data suggest 
that depletion of RELB in KRAS transformed cells inhibits proliferation and loss of RELA 
consequently results in decreased RELB expression. 
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Figure 3.2. RELB knockdown inhibits cell proliferation in KRAS transformed cells. A. Cell 
proliferation assay of KRAS transformed (SAKRAS) cells treated with the stated siRNA using the 
xCELLigenence system. Cells were plated 24 hours post siRNA transfection. B. Relative RELB mRNA 
expression normalized to the siCTL treated SAKRAS cells as determined by qRT-PCR. 
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3.3.3. RELB knockdown inhibits cell proliferation in KRAS mutant lung and 
pancreatic cancer cell lines 
We observed that decreased RELB expression inhibited cell proliferation in our 
KRAS transformed (SAKRAS) cell line. Next we determined whether the suppression of 
RELB in established human cancer cell lines would reproduce the proliferation effects 
we observed in our isogenic SAKRAS cell based model. RELB was depleted using 
siRNA in A549 lung cancer cells (KRAS G12S) and MIA PaCa-2 pancreatic cancer cells 
(KRAS G12C). Both A549 and MIA PaCa-2 cells grown on traditional cell culture plates 
displayed decreased cell proliferation when RELB was suppressed using siRNA (Figure 
3.3A-B). Moreover, these cell lines showed decreased nonadherent growth as 
measured by nonadherent colony formation in soft agar assays (Figure 3.3C-D). The 
effects of transient RELB suppression on nonadherent growth suggests an important 
role for RELB in KRAS mutant cancer cells. Notably, the depletion of RELB was 
observed to have a greater effect in A549 cells compared to MIA PaCa-2 cells. 
Therefore, we used the A549 lung cancer cell line to rule out siRNA specific artifacts – 
we measured proliferation defects associated with RELB suppression using shRNA and 
CRISPR/Cas9 technologies. 
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Figure 3.3. RELB knockdown inhibits colony growth in KRAS mutant cancer cell lines. A. Cell 
proliferation assay comparing MIA PaCa-2 pancreatic cancer cells transfected with siRNA targeting RELB 
and KRAS. B. Cell proliferation assay comparing A549 lung cancer cells transfected with siRNA targeting 
RELB and KRAS. C. Images showing nonadherent colony growth in soft agar assay using MIA PaCa-2 
pancreatic cancer cells transfected with siRNA targeting RELB and KRAS. (Bottom) Quantification of 
number of colonies formed in knockdown cells and (Bottom right) relative mRNA levels in RELB 
knockdown cells. D. Images showing nonadherent colony growth in soft agar assay using A549 lung 
cancer cells transfected with siRNA targeting RELB and KRAS. (Bottom) Quantification of number of 
colonies formed in knockdown cells and (Bottom right) relative mRNA levels in RELB knockdown cells. 
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3.3.4. The effects of RELB depletion in A549 lung cancer cells using shRNA and 
CRISPR/Cas9 systems 
To determine whether the effects of transient RELB suppression on cell growth 
could be reproduced using other stable mechanisms. We treated A549 cells with 
shRNA targeting RELB and measured cell proliferation (Figure 3.4A-B). In addition, 
A549 cells were infected with three different sgRNAs targeting different regions of the 
RELB gene and the resulting single cell clones where selected, expanded, and assayed 
for differences in cell growth as measure by cell doubling time (Figure 3.4C-E). 
Surprisingly, only one of the six RELB KO clones (clone F4) showed a significant 
difference in doubling time (Figure 3.4E). We observed less significant effects on cell 
proliferation, the longer RELB was depleted – in decreasing order from siRNA, to 
shRNA, to CRISPR knockout. Based on these results, we hypothersized that RELB 
effects seen with transient RELB suppression are either an off-target effects of the 
siRNA treatment or that long term RELB suppression may be leading to reprogramming 
and compensatory rescuing of the initial growth effects originally observed with siRNA 
depletion. To explore these effects in a different model, we depleted RELB in mouse 
pancreatic tumor cells. 
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Figure 3.4. Long term suppression of RELB in KRAS mutant A549 lung ancer cells. A. Western blot 
showing RELB protein expression in cells treated with shRNA against RELB. B. Cell proliferation assay 
showing A549 lung cancer cells transduced with shRNA targeting RELB. C. Western blot showing single 
clone selection of RELB KO clones. D.  Cell proliferation assay showing log phase of RELB KO clones 
used to measure doubling time. E. The doubling time of RELB KO clones, with only F4 clone showing 
siggnificant increase in doubling time (slower growth rate). 
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3.3.5. The effects of RELB depletion in mouse KPC tumor cells using shRNA 
To determine whether the effects of transient RELB suppression on cell growth 
could be reproduced using other models, we treated mouse KPC 4662 pancreatic tumor 
cells with siRNA and shRNA targeting RELB and measured cell proliferation (Figure 
3.5). The transient knockdown of RELB showed a significant growth defect relative to 
the control siRNA (Figure 3.5A). For the shRNA experiment, 5 different oligos were 
tested, yeilding one shRNA that effectively silenced RELB expression (Figure 3.5C). 
This shRNA #5 was used to transduce the KPC 4662 mouse pancreatic tumor cells. 
Again, we observed attenuated cell proliferation with RELB suppression; however, the 
effects seemed to be reduced in the shRNA treated cells (Figure 3.5E), compared to 
the transient siRNA depletion(Figure 3.5A). These findings along with our observations 
with long term suppresion in A549 cells (Figure 3.4), suggest that transient RELB 
suppression leads to a proliferation defect; however, cells may repond by inducing a 
compensatory pathway that begins to overcome the long term suppression of RELB. 
Keeping these results in mind, we perfomed pilot in vivo studies to determine whether 
we could observe effects on tumor growth in a mouse model. 
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Figure 3.5. The effects of RELB depletion in mouse KPC tumor cells using shRNA. A. Cell 
proliferation assay showing mouse KPC pancretic tumor cells transfected with siRNA targeting RELB B. 
Western blot showing different shRNAs tested for RELB suppresion. C. Western blot showing RELB 
protein expression in cells transduced with shRelb. D. Relative mRNA expression in cells transduced with 
shRelb. E. Cell proliferation assay showing mouse KPC pancretic tumor cells transduced with shRNA 
targeting RELB 
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3.3.6. The effects of RELB depletion in mouse KPC orthotopic pancreatic 
xenografts 
Although we began to observe reduced effects of long term RELB suppression, 
we perfomed pilot in vivo studies to determine whether we could observe effects on 
tumor growth in a syngeneic mouse model. Unfortunately, we see no significant 
differences in tumor incidence, number, or size, between shRelB transduced xenografts 
compared to controls (Figure 3.6). The KRAS LSL-G12D/+;Trp53LSL-R172H/+;Cre 
(KPC) 4662 mouse pancreatic tumor cell line (Hingorani et al., 2005) was transduced 
with shRelB. Ten WT C57Bl/6J mice were injected orthotopically with ~100,000 cells 
into the pancreas (5 with scrambled shRNA and 5 with shRelb cells). After ~4 weeks the 
scrambled control and shRelb mouse pairs were euthanized and the tumors were 
weighed and processed for mRNA & protein analysis. 
Although the bolus of tumor cells were injected orthotopically into the pancreas, 
when the tumors were harvested, we observed that the majority of the mice harbored 
tumors in two distinct regions - encased in the pancreas as expected and against the 
body wall, with some of these tumors being even larger potentially due to the reduced 
steric hinderance in this location. Taken together, these data suggest that RELB 
depletion does not affect tumor size in vivo. However, based on the consistent effects 
observed in vitro and work by other groups, RELB may be more important for other 
indications, such as migration, EMT, and metastasis in vivo (Bakhoum et al., 2018; 
Hamidi et al., 2012). 
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Figure 3.6. The effects of RELB depletion in mouse KPC xenografts. A. Western blot showing RELB 
expression in harvested mouse tumor xenografts. Red boxes denote samples that are equally loaded as 
measured by beta-actin levels. B. Plots showing tumor weights from orthotopic tumors in the mouse 
pancreas, tumors escaping pancreas into the body wall, and combined weights of all the tumors in each 
mouse. Siblings are color coded. C. Images of gross tumor histology from each mouse. 
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3.3.7. RELB dependent expression in KRAS transformed SAKRAS cells 
Finally, we perfomed a microarray to explore the transcriptional effects of RELB 
suppression. The KRAS transformed lung epithelial (SAKRAS) cells were transfected 
with siRNA against RELB, harvested and processed for RNA 96 hours post transfection. 
Interestingly, RELB appeared to be acting as a repressor for a subset of genes, 
including TGFβR3, an important protein involved in cell state determination (Figure 
3.7A). RELB depletion results in the upregulation of TGFβR3 in the KRAS wild type 
(SALEB) cells; however, the relative increase in the KRAS G12V SAKRAS cells is 
significantly greater (Figure 3.7B). The upregulation of TGFβR3 expression in 
reproducible in a number of KRAS mutant cell lines including MDA-MB-231 (G13D), 
A549 (G12S), MIA PaCa-2 (G12C), and PANC-1 (G12D) cells (Figure 3.7C). 
Potentially, this may be a relevant mechanism linking RELB to EMT, migration and 
metastasis and could explain why we were not able to see proliferation effects as a 
result of RELB suppression. Indeed, if RELB plays a role in EMT or metastasis, 
proliferation may not be the primary process affected by RELB depletion in vivo. More 
studies are needed, with the assays capable of measuring migration and metastasis, in 
order to determine the importance of RELB in these processes. 
TGFβ1 in conjunction with a SMAD2 luciferase reporter was used to determine 
whether RELB or TGFβR3 depletion would decrese pathway activity. RELB and 
TGFβR3 suppression led to a decrease in TGFβ pathway activation as measured by the 
SMAD2 reporter. However, surprisingly, the double knockdown returned the pathway to 
control levels. More experiments are needed to elucidate the intricacies of this network. 
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Figure 3.7. The effects of RELB suppression on transcription in KRAS transformed cell lines. A. 
Microarray of SAKRAS cells with RELB knockdown. B-C. Relative TGFβR3 expression with RELB 
knockdown in a panel of KRAS mutant cell lines. D. SMAD2 reporter in A549 cells measing TGFβ 
pathway activation with RELB and TGFβR3 depletion. E. Cell proliferation in MIA PaCa-2 pancreatic 
cancer cells with RELB and TGFβR3 suppression. 
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3.4. DISCUSSION 
Recently published findings, have suggested a role for RELB in EMT and cell 
migration (Bakhoum et al., 2018). Cells often undergo EMT resulting in enhanced 
motility, invasiveness, and metastasis. Acquisition of an EMT is also associated with 
increased cancer stemness and therapeutic resistance. Our study suggests that 
although RELB plays a role in cell proliferation in vitro, RELB is not observed to have a 
significant role in tumor growth in vivo. However, an important role for this noncanonical 
NF-κB subunit may be in cell migration and cell state determination via EMT. Further 
studies are needed using assays appropriate for indications, such as metastasis, to 
determine whether RELB is essential for these important processes in a KRAS mutant 
background. 
Together with recently published findings, our study suggests that although 
RELB plays a role in cell proliferation in vitro, another important role for this 
noncanonical NF-κB subunit may be in cell migration and cell state determination via 
EMT. Further studies are needed using assays appropriate for indications, such as 
metastasis, to determine whether RELB is essential in these important processes. 
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3.5. MATERIALS AND METHODS 
Cell Culture 
Low passage SALEB and SAKRAS cells were generous gifts from Dr. Scott H. Randell 
(UNC-Chapel Hill) and were grown as described previously (Lundberg et al., 2002). All 
other cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM; Gibco) 
supplemented with 10% fetal bovine serum (FBS; EMD Millipore) (MIA PaCa-2 are 
supplemented with 2.5% horse serum). Cell lines were used for no longer than 6 
months before being replaced. Stable cell lines were generated by selection in 2ug/ml 
puromycin. 
 
Western Blot Reagents 
Cells were lysed in 1% NP-40 lysis buffer (phosphatase and protease inhibitors from 
Sigma-Aldrich added fresh). Protein extracts were quantified by Bradford assay (Bio-
Rad Laboratories) and analyzed by SDS-PAGE. Blot analyses were done with phospho-
specific antibodies and antibodies recognizing total protein to control for total protein 
expression. Antibody to KRAS4B was obtained from Calbiochem. Antibody for β-actin 
was used to verify equivalent loading of total cellular protein. Antibodies from Cell 
Signaling Techonology unless otherwise stated.  
 
Small Molecule Inhibitors 
Inhibitors for in vitro studies were dissolved in dimethyl sulfoxide (DMSO) to yield a 10 
mM or 20 mM stock concentration and stored at -20 or -80°C, respectively. 
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siRNA and shRNA Transfection Reagents 
The following human siRNA (siGenome SMARTpool) was purchased from Dharmacon 
as a pool of four annealed dsRNA oligonucleotides: KRAS (L-005069–00) and non-
targeting control #3 (D-001210-03). Dharmafect transfection reagent 1 was used to 
transfect 20-40nM siRNA according to manufacturer’s instruction and cells were 
harvested 96 hours after transfection. 
 
Animal Studies 
Retroviral transduction of the KrasLSL-G12D/+;Trp53LSL-R172H/+;Cre (KPC) 4662 
pancreatic tumor cell line (Hingorani et al., 2005) with shRelB. Confluent HEK 293T 
packaging cells (70%–90%) were transfected with the plasmid and a packaging mix 
using PEI to produce viral supernatant. KPC 4662 cells were plated in a 6-well plate 
until reaching 50% confluence. Cells were washed, and 2 ml of a 1:2 virus/DMEM 
solution was incubated for 48 hours (diluted at 24 hours with an additional ml of DMEM). 
Tubes were prepared with 100,000 KPC 4662 GFP tumor cells in a 50ul 1:1 mix of 
1xPBS:Matrigel for each condition - (i) pLKO.1 shRNA scrambled ctrl & (ii) pLKO.1 
shRelB. The 10 WT C57Bl/6J mice were shaved and prepared and Dr Yuliya Pylayeva-
Gupta performed surgery - injecting ~100K cells into the pancreas of each mouse. Mice 
were placed on a warming pad and were monitired until the last mouse regained 
consciousness. The mice were monitored every other day. After ~4 weeks the 
scrambled control and shRelb mouse pairs were euthanized. Dr Pylayeva-Gupta 
removed the relevant tissue and tumors from the pancreas & body wall, and they were 
sorted and labeled the tumors. Finally, I weighed the tumors and cut 2 pieces of each 
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tumor for mRNA & protein analysis. The remainder of tissue and each tumor is 
incubated in 10% formalin for 48hrs, then delivered to the histology core in 70% EtOH 
for paraffin embedding. All animal studies were approved by the Division of 
Comparative Medicine (DCM) at UNC-CH. 
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CHAPTER IV: CONCLUSION 
4.1. THESIS SUMMARY 
The overall objective of this thesis work was twofold: (1) to describe the 
differential DNA methylation associated with mutant KRAS expression and (2) to 
explore the role of the noncanonical NF-κB transcription factor, RELB, in KRAS mutant 
cells. 
In chapter 2, we analyze the DNA methylation profiles of KRAS-dependent 
pancreatic cancer cell lines and perform KRAS knockdown to determine whether their 
DNA methylation signatures rely on persistent KRAS signaling. Analysis of 11 KRAS 
mutant pancreatic cells reveal basal CpG methylation patterns that are strikingly similar 
between cell lines (MAD <0.1 beta value for 70% of CpGs). However, KRAS knockdown 
results in differential DNA methylation patterns largely specific to each cell line. In 
Pa16C pancreatic cells, while KRAS knockdown results in over 8000 differentially 
methylated (DM) CpGs, treatment with the ERK inhibitor SCH772984 shows less than 
40 DM CpGs, suggesting that ERK is not a broadly active driver of KRAS-associated 
DNA methylation. To measure the effects of KRAS overexpression in cells with a 
separate lineage, we compared immortalized KRAS G12V transformed lung epithelial 
cells to non-transformed controls. We identified >50,600 DM CpGs in lung cells 
overexpressing KRAS G12V, with many located at the promoters of important tumor 
suppressors and oncogenes. Finally, gene ontology analysis of the DM CpGs from both 
lung and pancreatic cells shows enrichment for genes involved in differentiation and 
 113 
development. This group of epigenetically regulated genes associated with KRAS 
expression represents potential therapeutic targets in KRAS-driven cancer. Ultimately, a 
better understanding of the DNA methylation events associated with oncogenic KRAS 
expression could enhance therapeutic approaches for KRAS-driven cancers. 
In chapter 3, we explored effects of the noncanonical NF-κB pathway in KRAS 
mutant cells and better understand the role of the NF-κB transcription factor subunit, 
RELB. Our findings suggest that RELB expression is upregulated in KRAS mutant cells 
in vitro and in vivo. Interestingly, in previous DNA methylation studies, we also observed 
hypomethylation at the RELB promoter in cells expressing KRAS G12V. In lung and 
pancreatic cancer cell lines expressing mutant KRAS, RNAi against RELB decreases 
proliferation and nonadherent colony growth. However, depletion of RELB did not show 
significant effects on proliferation in murine xenograft and genetic models. Models 
designed to assess migration, metastasis, and cell-state transitions associated with 
RELB expression could yield more actionable results in future studies. Together, these 
results suggest that mutant KRAS leads the upregulation of RELB expression, and 
supports an important role for the noncanonical NF-κB pathway as a potential 
therapeutic target in KRAS-driven malignancies.  
 In summation, this thesis work describes the differential DNA methylation 
associated with oncogenic KRAS expression. Although these methylation changes are 
cell specific, if the DNA methylation profile in these cells are susceptible to KRAS 
depletion, gene promoters involved in development and differentiation appear to be 
consistently impacted. This work reinforces the complexity of the RAS signaling 
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pathway and offers potentially new avenues for therapeutic purposes. The implications 
of these findings are further discussed below. 
 
4.2. DISCUSSION  
Although, the KRAS gene is one of the most commonly mutated genes in cancer, 
attempts to directly target oncogenic KRAS have been unsuccessful. In addition to 
aberrant signaling, the expression of mutant KRAS is correlated with global differential 
DNA methylation. Therefore, KRAS-mediated epigenetic reprogramming could be an 
avenue where the survival of KRAS-dependent cancer cells may be vulnerable. Our 
study describes the differential DNA methylation associated with the knockdown and 
overexpression of oncogenic KRAS in pancreatic and lung cells. We analyzed the DNA 
methylation profiles in a panel of KRAS mutant pancreatic cancer cells and observed 
strikingly similar patterns (Figure 2.1). To determine whether these methylation patterns 
are stable, or dependent on KRAS expression, we silenced KRAS in 10 of the cell lines 
using shRNA (Figure 2.2). Although the basal DNA methylation patterns of the control 
cells are similar, the differential DNA methylation associated with KRAS knockdown 
showed patterns unique to each cell line. To determine whether the effects of KRAS 
knockdown are ERK-dependent, Pa16C cells were treated with the ERK inhibitor 
SCH772984 (Figure 2.3). Interestingly, we observe <40 DM CpGs with ERK inhibition 
compared to 8,877 DM CpGs with KRAS shRNA in the Pa16C cells. Finally, to identify 
differential DNA methylation associated with mutant KRAS overexpression, we 
compared immortalized KRAS G12V transformed lung epithelial SAKRAS cells to non-
transformed SALEB controls. In the lung epithelial cells, a great number of DM CpGs 
 115 
correlated with the overexpression of KRAS G12V (>50,600 DM CpGs and >500 
affected gene promoters) (Figure 2.5) compared to KRAS suppression in Pa16C cells 
(Figure 2.2). Together, these data suggest that the majority of differential DNA 
methylation associated with KRAS knockdown is cell-specific. KRAS depletion using 
shRNA yields greater DM CpGs compared the ERK inhibitor treatment, suggesting that 
the loss of KRAS affects the methylation profile in an ERK-independent manner. 
Furthermore, KRAS overexpression is associated with a greater number of DM CpGs 
compared to KRAS suppression. 
Although the basal DNA methylation patterns of the pancreatic cancer cell lines 
are similar (Figure 2.1), the differential DNA methylation associated with KRAS 
knockdown showed patterns unique to each cell line. The number of DM CpGs ranges 
from dozens to thousands depending on the cell line (Figure 2.2E). Moreover, we only 
observed 204 DM CpGs common in at least 3 of the pancreatic knockdown cells, and 
none of these DM CpGs were shared between more than 4 of the 10 cell lines (Figure 
2.4A). This suggests a cell line specific epigenetic response to KRAS depletion and that 
the methylation profile of some cells may be more vulnerable to KRAS knockdown than 
others (Figure 2.2E). A number of studies suggest that the majority of the differential 
DNA methylation associated with cancer may be a consequence of transformation that 
is stochastic in nature - contributing to low levels of overlap and high heterogeneity 
between cell lines (even when they share the same genetic background and/or origin) 
(Burga et al., 2011; Feinberg, 2014; Hanna et al., 2009; Landan et al., 2012; Raj and 
van Oudenaarden, 2008; Xie et al., 2018). While our studies showing similarity between 
9 of 11 pancreatic cell lines relative to their methylation patterns could be used as an 
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non stochastic, however the contriution of the cell lineage may largely determine the 
patterns observed. The majority of the DM CpGs observed in this study appear to be 
specific to each cell line. The proapoptotic gene FAS has been reported to undergo 
HRAS-mediated epigenetic silencing in fibroblasts (Gazin et al., 2007); however, this 
was not observed in the panel of pancreatic cell lines. The epigenetic silencing of the 
IRAK3 gene has also been reported in KRAS mutant cells and other tissues, and this 
was not observed in the panel of pancreatic cell lines (De Carvalho et al., 2012). 
Therefore, certain DNA methylation events, which may be critical for survival in certain 
cell lines, may be inconsequential in others. Although, many of these DNA methylation 
changes could be stochastic in nature and simply “passenger” events, or a 
consequence of their cell state and cell lineage, KRAS may still influence key changes 
to the epigenome that are ultimatley crucial for the cancer phenotype. More studies are 
needed to determine whether stratification will produce correlations strong enough to 
permit the prediction of cancer subtypes based on the methylation patterns or vice 
versa. 
Another interesting observation is the difference between the number of DM 
CpGs associated with KRAS knockdown and KRAS overexpression - there are 
significantly less DM CpGs associated with KRAS suppression. KRAS remains crucially 
linked to cell proliferation through ERK, its main effector, and inhibition of this pathway 
reliably leads to growth suppression (Figure 2.3) (Hayes et al., 2016). However, the 
question remains, if not ERK, which KRAS effectors are leading to the thousands of 
DNA methylation changes we observe. In mouse lung adenocarcinoma cells, YAP1 was 
able to rescue KRAS depleted cells, suggesting a relevant mechanism to bypass loss of 
 117 
KRAS signaling (Shao et al., 2014). In the same study KRAS also induces PI3K 
expression, and yet, the subsequent suppression of KRAS has no effect on the 
upregulated AKT activation. PI3K has been shown to compensate for KRAS 
suppression in pancreatic cancer cells and regulate epigenetic modifiers including 
DNMTs (Fagnocchi et al., 2016). KRAS knockdown cells display sensitivity to PI3K 
inhibitors and dual PI3K and MEK inhibitors have been found to be more effective than 
blocking the individual pathways alone (Muzumdar et al., 2017). If proteins such as 
YAP1 and PI3K play a role downstream of KRAS to induce epigenetic changes, this 
could explain why significantly less DM CpGs are associated with KRAS suppression 
compared to overexpression. A KRAS effector pathway such as PI3K, which is 
upregulated upon mutant KRAS expression, could be responsible for many of the 
methylation changes observed. The majority of differential DNA methylation associated 
with KRAS expression could be mediated by effector pathways similar to PI3K that are 
refractory to KRAS suppression, while a minority would be directly dependent KRAS 
signaling. Upon KRAS suppression, sustained PI3K activity may be able maintain the 
majority of methylation changes induced by mutant KRAS. This kind of sustained 
activity by effector pathways could maintain the methylation status of the majority of the 
changes initially induced by mutant KRAS expression (Figure 4.1). This would explain 
why such a modest number of CpGs are DM in response to KRAS suppression. Once 
cells have been transformed and DNA methylation changes have been established 
following mutant KRAS expression, the large majority of these changes may no longer 
be tied to the presence or absence of KRAS activity, even as the cell’s growth and 
survival are still tied to KRAS expression. DNA methylation profiling in the presence of a 
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PI3K inhibitor could shed light on these questions, along with how reversion of the 
KRAS-induced methylation changes can affect cell state and cell differentiation. 
Many of the DM CpGs associated with KRAS overexpression in our study are 
located at the promoters of important tumor suppressors, oncogenes, transcription 
factors, and regulators of differentiation. Moreover, gene ontology analysis revealed an 
enrichment for differentially methylated genes involved in differentiation and 
development. The regulation of pluripotency and lineage-specific genes require the 
integration of multiple signaling pathways, epigenetic modifiers, and transcription factors 
(Wang et al., 2017). In response to KRAS suppression, KRAS-driven cells may rely on 
compensatory survival pathways such as the PI3K pathway. PI3K/AKT has been shown 
to affect the expression of differentiation and stemness genes. In our Pa16C KRAS 
knockdown cells, a number of these genes appear to be differentially methylated in 
response to KRAS suppression (Figure 2.4). The promoter of FGF9, a gene reported to 
activate AKT signaling, is hypomethylated (Lai et al., 2014)(Sun et al., 2015). The 
promoter of NRG3, a ligand that activates HER3, an EGFR member of receptor tyrosine 
kinase (RTK) signaling upstream of PI3K/AKT, is hypomethylated (Mujoo et al., 2014). 
The promoter of GDNF, which can also activate PI3K, is hypomethylated. POU3F2 and 
OLIG2 were both hypomethylated - two out of the four genes, from a core set of 
neurodevelopmental transcription factors (POU3F2, SOX2, SALL2, and OLIG2) 
essential for GBM propagation. These transcription factors coordinately bind and 
activate regulatory elements sufficient to fully reprogram differentiated GBM cells into 
tumor propagating stem-like cells (Suvà et al., 2014). 
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Figure 4.1. Hypothetical model showing epigenetic regulation of developmental genes by mutant 
KRAS. Activating KRAS mutations lead to persistant induction of effector pathways that drive the cancer 
phenotype including the differential DNA methylation of genes involved in development and 
differentiation. In some cell lines, effector pathways such as PI3K and others, are able to maintain their 
abberant activity independent of KRAS signaling. As a consequence of feed forward loops initiated by 
mutant KRAS, kinome reprogramming, or the establishment of stable epigenetic patterns, the majority of 
DNA methylation changes associated with mutant KRAS activity remains refractory to KRAS suppression. 
However, independent of the changes in DNA methylation, KRAS knockdown and ERK inhibition still both 
lead to growth arrest in KRAS driven cell lines. SCH772984, type I and type II ERK inhibitor. 
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Another promoter hypomethylated upon KRAS knockdown is HOXA9, a major 
transcription factor that regulates stem cells during development. Aberrant expression of 
HOX genes occurs in various cancers, and HOXA9 transcriptomes are specifically 
associated with cancer stem cell features (Seifert et al., 2015). Hypomethylated CpGs 
were also found at the BMP3 promoter. BMPs are implicated in activation of signaling 
pathways that drive epithelial-mesenchymal transition (EMT), including WNT signaling, 
TGFB signaling and PI3K signaling, all important pathways in pancreatic cancer cells 
(McCormack et al., 2013; Shao et al., 2014; Zabkiewicz et al., 2017). And finally, 
another promoter which appeared as hypomethylated was TWIST1, a canonical EMT 
transcription factor shown to promote cancer stem cell properties (Mani et al., 2008). 
Overexpression of TWIST1 is reported to override Myc-induced apoptosis in tumor cells 
and along with the other changes, could be a compensatory response by the Pa16C 
KRAS mutant pancreatic cells to survive KRAS suppression. In the study by Shao et al., 
the authors looked for transcriptional programs regulated by both KRAS and YAP1 in 
microarray data and found the top gene sets enriched included several related to 
differentiation and development, similar to what we found with our gene ontology 
analysis (Shao et al., 2014) (Figure 2.8). 
Together, our findings suggest that oncogenic KRAS expression is associated 
with differential DNA methylation and KRAS overexpression may affect a greater 
number of CpGs compared to KRAS knockdown due to sustained activity of KRAS 
effector pathways even in KRAS knockdown cells. This would explain why we observe 
such a discrepancy between the high number of DM CpGs correlated with KRAS 
overexpression compared to the modest changes we see with KRAS knockdown. This 
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study describes the differential DNA methylation associated with oncogenic KRAS 
expression and suggests that although these methylation changes are cell specific, the 
biological processes that are impacted may overlap. If the DNA methylation profile in 
these cells are susceptible to KRAS depletion, gene promoters involved in development 
and differentiation appear to be consistently impacted. This has been explored in 
previous studies (Xie et al., 2018) and may be an avenue deserving of more work in the 
search for supplementary strategies to target KRAS-driven cancers. 
This thesis work also focuses on the noncanonical NF-κB pathway in KRAS 
mutant cells and better understand the role of the NF-κB transcription factor subunit, 
RELB. Our findings suggest that RELB expression is upregulated in KRAS mutant cells 
in vitro and in vivo. Interestingly, in previous DNA methylation studies, we also observed 
hypomethylation at the RELB promoter in cells expressing KRAS G12V. In lung and 
pancreatic cancer cell lines expressing mutant KRAS, RNAi against RELB decreases 
proliferation and nonadherent colony growth. However, depletion of RELB did not show 
significant effects on proliferation in murine xenograft and genetic models. Models 
designed to assess migration, metastasis, and cell-state transitions associated with 
RELB expression could yield more actionable results in future studies. Together, these 
results suggest that mutant KRAS leads the upregulation of RELB expression, and 
supports an important role for the noncanonical NF-κB pathway as a potential 
therapeutic target in KRAS-driven malignancies. 
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4.3. FUTURE DIRECTIONS 
The importance of activation of RAS signaling in cancer pathogenesis is 
indisputable. However, it is becoming more apparent that effective treatment of KRAS 
driven cancers will entail a combinatorial approach rather than single agent targeting of 
the KRAS pathway effectors. Co-administration of ERK and PI3K inhibitors or other 
combinations will be an effective treatment strategy for KRAS mutant cancer in the 
clinic, particularly once hurdles associated with cell toxicity can be overcome. However, 
the epigenetic changes associated with mutant KRAS expression could be another 
avenue where KRAS driven cancer cells may be vulnerable. 
In chapter 2, we discuss how KRAS expression is associated with genome-scale 
changes in DNA methylation. We show that KRAS suppression leads to ERK-
independent, cell specific differential methylation in a panel of pancreatic cancer cell 
lines. To follow up on these studies, a comparison between the methylation profiles of 
patient tumor samples and the pancreatic panel, may allow us to predict tumor 
methylomes that are likely to respond to KRAS suppression or KRAS effector inhibition 
and tumors that are likely to be refractory. To better understand the timing of KRAS 
mediated methylation changes we could use inducible KRAS expression and analyze 
the DNA methylation changes over time. Although, the comparison of the methylation 
profiles in the isogenic SALEB and SAKRAS pair was informative. The use of an 
inducible KRAS expression vector to monitor the methylation changes in a panel over 
time would be an exciting follow up analysis. We could also determine whether the 
specific type of KRAS mutation affects these methylation changes by comparing the 
effects of the most prevalent single amino acid substitutions. 
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In chapter 3, we explore the role of the noncanonical NF-κB transcription factor 
RELB in KRAS mutant cells. While there are many studies in which KRAS signaling 
mediates cancer phenotypes through the canonical NF-κB pathway, few studies have 
explored a role for the noncanonical NF-κB pathway. We showed that suppression of 
the canonical RELA/p65 transcription factor also decreases RELB expression. Based 
on this observation, many of the effects attributed to the canonical RELA transcription 
factor could actually be a result of downregulation of RELB. To follow up on these 
studies, we could attempt to elucidate the roles of RELB previously attributed to RELA. 
In addition, it will be important to determine the role of RELB in vivo. Recently published 
findings, have suggested a role for RELB in EMT and cell migration (Bakhoum et al., 
2018). Cells often undergo EMT resulting in enhanced motility, invasiveness, and 
metastasis. Acquisition of an EMT is also associated with increased cancer stemness 
and therapeutic resistance. Our study suggests that although RELB plays a role in cell 
proliferation in vitro, RELB is not observed to have a significant role in tumor growth in 
vivo. However, an important role for this noncanonical NF-κB subunit may be in cell 
migration and cell state determination via EMT. Further studies are needed using 
assays appropriate for indications, such as metastasis, to determine whether RELB is 
essential for these important processes in a KRAS mutant background. 
  
 124 
4.4. FINAL NOTE 
The goal of this thesis work was to gain an understanding of RAS signaling that 
would inform the development of rational therapeutic approaches for KRAS driven 
malignancies. Here we discovered that oncogenic KRAS expression is associated with 
differential DNA methylation and KRAS overexpression may affect a greater number of 
CpGs compared to KRAS knockdown due to sustained activity of KRAS effector 
pathways even in KRAS knockdown cells. This would explain why we observe such a 
discrepancy between the high number of DM CpGs correlated with KRAS 
overexpression compared to the modest changes we see with KRAS knockdown. 
Finally, gene ontology analysis of the DM CpGs from both lung and pancreatic cells 
shows enrichment for genes involved in differentiation and development. This group of 
epigenetically regulated genes associated with KRAS expression represents potential 
therapeutic targets in KRAS-driven cancer. 
Our work also aimed to uncover novel effects of the noncanonical NF-κB 
pathway in KRAS mutant cells and better understand the role of the NF-κB transcription 
factor subunit, RELB. Our findings suggest that RELB expression is upregulated in 
KRAS mutant cells in vitro and in vivo. Interestingly, in previous DNA methylation 
studies, we also observed hypomethylation at the RELB promoter in cells expressing 
KRAS G12V. In lung and pancreatic cancer cell lines expressing mutant KRAS, RNAi 
against RELB decreases proliferation and nonadherent colony growth. However, 
depletion of RELB did not show significant effects on proliferation in murine xenograft 
and genetic models. Models designed to assess migration, metastasis, and cell-state 
transitions associated with RELB expression could yield more actionable results in 
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future studies. Together, these results suggest that mutant KRAS leads the upregulation 
of RELB expression, and supports an important role for the noncanonical NF-κB 
pathway as a potential therapeutic target in KRAS-driven malignancies. 
Overall, this thesis work underlines the complexity of KRAS signaling in cancer 
and may potentially offer insights for diagnostic and therapeutic purposes. The great 
number of effector pathways downstream of oncogenic KRAS suggest combination 
therapy may likely be the most promising approach, even as we work diligently toward 
targeted KRAS inhibition. Ultimately, prophylactic measures are likely to remain our best 
hope against cancer. A public emphasis on prevention would likely lower cancer 
incidence dramatically – a healthy diet, exercise, taking steps to decrease inflammation, 
and avoiding carcinogenic vices like cigarette smoke. More research is needed to 
develop more sophisticated countermeasures against KRAS mutant cancer, but I 
remain optimistic in our potential to improve and extend the quality of the lives of 
patients afflicted with these cancers. 
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